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A B S T R A C T
Background
Post-stroke fatigue (PSF) is a common and distressing problem after stroke. The best ways to prevent or treat PSF are uncertain. Several
different interventions can be argued to have a rational basis.
Objectives
To determine whether, among people with stroke, any intervention reduces the proportion of people with fatigue, fatigue severity, or
both; and to determine the effect of intervention on health-related quality of life, disability, dependency and death, and whether such
intervention is cost effective.
Search methods
We searched the Cochrane Stroke Group Trials Register (last searched May 2014), Cochrane Central Register of Controlled Trials
(The Cochrane Library, 2014, Issue 4), MEDLINE (1950 to May 2014), EMBASE (1980 to May 2014), CINAHL (1982 to May
2014), AMED (1985 toMay 2014), PsycINFO (1967 to May 2014), Digital Dissertations (1861 to May 2014), British Nursing Index
(1985 to May 2014), PEDro (searched May 2014) and PsycBITE (searched May 2014). We also searched four ongoing trials registries,
scanned reference lists, performed citation tracking of included trials and contacted experts.
Selection criteria
Two review authors independently scrutinised all titles and abstracts and excluded obviously irrelevant studies. We obtained the full
texts for potentially relevant studies and three review authors independently applied the inclusion criteria. We included randomised
controlled trials (RCTs) that compared an intervention with a control, or compared different interventions for PSF.
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Data collection and analysis
Two review authors independently extracted data and assessed risk of bias for each included trial. The primary outcomes were severity of
fatigue, or proportion of people with fatigue after treatment. We performed separate analyses for trials investigating efficacy in treating
PSF, trials investigating efficacy in preventing PSF and trials not primarily investigating efficacy in PSF but which reported fatigue as
an outcome. We pooled results from trials that had a control arm. For trials that compared different potentially active interventions
without a control arm, we performed analyses for individual trials without pooling.
We calculated standardised mean difference (SMD) as the effect size for continuous outcomes and risk ratio (RR) for dichotomous
outcomes. We pooled the results using a random-effects model and assessed heterogeneity using the I2 statistic. We performed separate
subgroup analyses for pharmacological and non-pharmacological interventions. We also performed sensitivity analyses to assess the
influence of methodological quality.
Main results
We retrieved 12,490 citations, obtained full texts for 58 studies and included 12 trials (three from the 2008 search and nine from
the 2014 search) with 703 participants. Eight trials primarily investigated the efficacy in treating PSF, of which six trials with seven
comparisons provided data suitable for meta-analysis (five pharmacological interventions: fluoxetine, enerion, (-)-OSU6162, citicoline
and a combination of Chinese herbs; and two non-pharmacological interventions: a fatigue education programme and a mindfulness-
based stress reductionprogramme).The fatigue severitywas lower in the intervention groups than in the control groups (244 participants,
pooled SMD -1.07, 95% confidence interval (CI) -1.93 to -0.21), with significant heterogeneity between trials (I2 = 87%, degrees of
freedom (df ) = 6, P value < 0.00001). The beneficial effect was not seen in trials that had used adequate allocation concealment (two
trials, 89 participants, SMD -0.38, 95% CI -0.80 to 0.04) or trials that had used adequate blinding of outcome assessors (four trials,
198 participants, SMD -1.10, 95% CI -2.31 to 0.11).
No trial primarily investigated the efficacy in preventing PSF.
Four trials (248 participants) did not primarily investigate the efficacy on fatigue but other symptoms after stroke. None of these
interventions showed any benefit on reducing PSF, which included tirilazad mesylate, continuous positive airway pressure for sleep
apnoea, antidepressants and a self management programme for recovery from chronic diseases.
Authors’ conclusions
There was insufficient evidence on the efficacy of any intervention to treat or prevent fatigue after stroke. Trials to date have been small
and heterogeneous, and some have had a high risk of bias. Some of the interventions described were feasible in people with stroke, but
their efficacy should be investigated in RCTs with a more robust study design and adequate sample sizes.
P L A I N L A N G U A G E S U M M A R Y
Interventions for post-stroke fatigue
Review question:We reviewed the evidence about the effect of any intervention that had been used to treat or prevent fatigue in people
with stroke.
Background: Fatigue is a common and distressing problem after stroke, but no intervention has been recommended to treat or prevent
it in people with stroke. Thus, it is important to find out if any intervention could reduce the presence or severity, or both, of fatigue
in people with stroke.
Study characteristics: The evidence is current to May 2014. We found 12 randomised controlled trials (clinical studies where people
are randomly put into one of two or more treatment groups) with 703 people with stroke. Of these 12 trials, eight trials recruited only
people with fatigue and were primarily intended to treat fatigue, no trial was primarily intended to prevent fatigue and the other four
trials were not primarily intended to treat or prevent fatigue but reported fatigue as an outcome.
Key results: There was insufficient evidence to support the use of any intervention to treat or prevent fatigue in people with stroke.
Quality of the evidence: The general study quality was low. The available data were limited as each identified intervention was only
investigated in a single trial. In addition, some trials were small and used poor study designs. Therefore, further trials of better quality
are needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interventions specifically aimed at treating post-stroke fatigue, compared with placebo, usual medical care or wait-list
Patient or population: people with stroke with fatigue
Settings: both inpatients and outpatients
Intervention: pharmacological interventions and non-pharmacological interventions
Comparison: placebo, usual medical care or wait-list




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Fatigue severity at the end
of pharmacological treat-
ment (assessed by differ-
ent fatigue scales)
Follow-up: at the end of
treatment
Not known Not known The fatigue severity was
lower in the pharmacologi-
cal treatment group than in
the control group: SMD -1.




more severe fatigue. The
negative value of SMD in-
dicates lower mean score
in the treatment group
compared with the control
group




Follow-up: at the end of
treatment
Not known Not known No significant difference
of fatigue severity be-
tween the non-pharmaco-
logical treatment group and
the control group: SMD -0.




SMD: standardised mean difference
1. The beneficial effect was not seen in trials using the adequate strategies for allocation concealment or those using adequate-blinding of
outcome assessors (risk of bias). In addition, there is substantial heterogeneity between the trials, but the available date were insufficient
for us to identify the source of heterogeneity (heterogeneity). Furthermore, this result did not provide information for the efficacy of any
specific intervention (indirectness).
2. Only two small trials (each with fewer than 20 participants) were identified, thus it is possible that these trials did not have adequate
power to detect clinical difference, rather than these interventions had no effect on fatigue (imprecision). In addition, neither trial used
















































































B A C K G R O U N D
Description of the condition
Fatigue is a common, distressing and long-term problem after
stroke. The reported proportion of people with post-stroke fatigue
(PSF) ranges from23%to75% (Choi-Kwon 2011). This variation
in proportion between studies reflects the heterogeneity in the
recruited participants, time since stroke and assessment methods
for fatigue. PSF is common immediately after stroke and it tends
to persist in most but not all people. It contributes to a lower
quality of life and a higher risk of death (Glader 2002; van de Port
2007). According to a national survey conducted in the UK, the
management and prevention of fatigue after stroke was ranked,
by people with stroke and health professionals, among the top 10
research priorities relating to life after stroke (Pollock 2012).
The aetiology or mechanism of PSF is unknown. A myriad of bi-
ological, psychosocial and behavioural factors might be associated
with fatigue (Wu 2015). One systematic review of biological cor-
relates of PSF showed that there was no conclusive evidence on the
association between PSF and lesion site (Kutlubaev 2012). One
single study found that PSF was associated with reduced excitabil-
ity of the motor cortex (Kuppuswamy 2015). Some small stud-
ies found associations between PSF and inflammatory biomarkers
(Syed 2007; Ormstad 2011; Ormstad 2014), and associations be-
tween PSF and attention deficits (Passier 2011; Radman 2012).
One systematic review of psychological associations of PSF found
that PSF was associated with depressive symptoms, and this as-
sociation existed even in people with stroke who did not meet
the clinical criteria of depression (Wu 2014a). In addition, some
studies found associations with anxiety, loss of control and pas-
sive coping (Wu 2014a). Another interesting hypothesis is that
fatigue may be associated with physical deconditioning, which is
common after stroke (Saunders 2013). Current evidence for this
hypothesis is limited: one study found an association between PSF
and lower limb extensor power (Lewis 2011), while another small
study found no association between PSF and any fitness indices
(Michael 2006). Furthermore, one longitudinal study found that
a lower level of physical activity at one month independently pre-
dicts a higher level of fatigue at six and 12 months’ follow-up
(Duncan 2015).
Description of the intervention
Since PSF may have several causative or maintaining factors (Wu
2015), there are a number of potential interventions, in combi-
nation or alone, that may be helpful. Possible interventions in-
clude pharmacological interventions (e.g. antidepressants, wake-
fulness stimulants), psychological interventions (e.g. cognitive be-
havioural therapy, educational programme) and physical training
(e.g. graded physical training, aerobic exercise).
How the intervention might work
Due to our lack of knowledge of the exact aetiology or mechanism
of PSF, it is unclear which approach may be effective in treating
or preventing PSF. In clinical practice, physicians may assess for
co-existing, treatable conditions such as anaemia, depression, hy-
pothyroidism and infection, but often these conditions are not
present in people with PSF.We could hypothesise that drugs, such
as antidepressants, which regulate neuroendocrine andneurotrans-
mitter systems, might reduce fatigue; that psychological interven-
tions, which improve mood and behaviours, might reduce fatigue
or that exercise, by means of reversing physical deconditioning,
might reduce fatigue.
Why it is important to do this review
Fatigue is a common and distressing problem after stroke but there
is uncertainty about how to manage it. Therefore, we performed
this systematic review using broad inclusion criteria with an aim
to identify any intervention that had been used to treat or prevent
PSF.
O B J E C T I V E S
Todeterminewhether, amongpeoplewith stroke, any intervention
reduces the proportion of people with fatigue, fatigue severity, or
both; and to determine the effect of intervention on health-related
quality of life, disability, dependency and death, and whether such
intervention is cost effective.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) in people with
a clinical diagnosis of stroke, where the interventions were used to
treat or prevent PSF. This included three groups of trials.
• Trials primarily intended to treat PSF: the aim of the
intervention was to treat fatigue (as stated by the trial
investigators), which required participants to have fatigue at
recruitment.
• Trials primarily intended to prevent PSF: the aim of the
intervention was to prevent fatigue (as stated by the trial
investigators) in people with stroke who did not have fatigue at
recruitment.
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• Trials not primarily intended to treat or prevent PSF but
which reported fatigue as an outcome: the aim of the
intervention was to improve health status or other symptoms
after stroke, and fatigue was pre-specified as an outcome. These
trials usually did not specify whether the participants had fatigue
at recruitment.
We excluded trials that used fatigue as a measure to assess whether
the intervention was tolerable in participants (i.e. whether the
intervention had induced intolerable tiredness during treatment)
rather than a measure to assess the therapeutic effect.
For trials using a cross-over design, we only included data from
the first phase, that is, before crossing over the treatment.
We included trials irrespective of their publication status and pub-
lication language.
Types of participants
We included adults (aged 18 years and over), men and women,
with a clinical diagnosis of stroke. We included all pathologi-
cal subtypes of stroke, including ischaemic stroke, haemorrhagic
stroke and subarachnoid haemorrhage (SAH). We included any
method of diagnosis or assessment of PSF, but it was not necessary
for participants to have fatigue at recruitment.
For trials reportingmixed populations of participants (e.g. a group
of people with either stroke or brain injury), we included them
only if more than 75% of the participants had had a stroke, or
if separate data for the people with stroke were reported by or
obtained from the trial investigators.
Types of interventions
We included pharmacological interventions and non-pharmaco-
logical interventions in combination or alone. We included any
trial that attempted to evaluate the following comparisons.
• A comparison between an intervention and a control (where
the control was either placebo, usual medical care or wait-list).
• A comparison between two or more different interventions,
with or without a control.
• A comparison between different doses or intensity of the
same type of intervention, with or without a control.
We anticipated that the types of interventions would include an-
tidepressants, other pharmacological agents, cognitive behavioural
therapy, educational programmes, counselling or physical exercise,
but we did not limit the review to these types of interventions.
Types of outcome measures
Primary outcomes
The primary outcome for this review was fatigue at the end of
treatment,measured as either the proportionof peoplewith fatigue
or the mean severity of fatigue, or both. Examples of possible
assessment measures included, but were not limited to:
• Fatigue Severity Scale (FSS) (Krupp 1989);
• Visual Analogue Scale for fatigue severity (VAS-f );
• self reported fatigue questionnaires;
• energy/fatigue scale from the Medical Outcomes Study (i.e.
Short Form-36 vitality subscale).
If a trial had used a number of different tools to assess fatigue,
we included the main outcome measure as specified by trial inves-
tigators. For instances where trial investigators had not specified
the main one, we specified the main outcome measure in order of
preference based on the following two criteria.
• A measure of fatigue designed specifically for stroke (e.g. a
case definition of PSF) (Lynch 2007); a generic measure for
fatigue that has been tested in stroke (e.g. Fatigue Assessment
Scale, Profile of Mood States - fatigue subscale, Short Form-36
vitality scale, Multidimensional Fatigue Symptom Inventory,
FSS, Functional Assessment of Chronic Illness Fatigue,
Neurological Fatigue Index) (Mead 2007; Tyson 2014); a generic
measure for fatigue that has not been previously tested in stroke.
• If the scales were in the same category according to the
above criterion, we specified the main outcome measure from
most commonly used scales (e.g. FSS) to less commonly used
scales in the publications identified in this review.
Secondary outcomes
• Health-related quality of life (e.g. Short Form-36).
• Disability (e.g. Barthel Index score).
• Dependence (e.g. modified Rankin scale; mRS).
• Death.
• Cost effectiveness.
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module.We searched for trials in all languages and arranged trans-
lation of relevant papers published in languages other than En-
glish.
Electronic searches
We performed updated searches of the following electronic
databases and trials registers from the previous searches in 2008
to May 2014.
• Cochrane Stroke Trial Register (searched May 2014).
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, 2014 Issue 4) (Appendix 1).
• MEDLINE (1950 to May 2014) (Appendix 2).
• EMBASE (1980 to May 2014) (Appendix 3).
• CINAHL (1982 to May 2014) (Appendix 4).
• AMED (1985 to May 2014) (Appendix 5).
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• PsycINFO (1967 to May 2014) (Appendix 6).
• ProQuest Dissertations and Theses Database (1861 to May
2014) (Appendix 7).
• British Nursing Index (1985 to May 2014) (Appendix 8).
• PEDro (www.pedro.fhs.usyd.edu.au/) (May 2014).
• PsycBITE (www.psycbite.com) (May 2014).
• ISRCTN (www.isrctn.com/) (May 2014).
• Trials Central (www.trialscentral.org/) (May 2014).
• Stroke Trials Registry (www.strokecenter.org/trials/) (May
2014).
• Health Service Research Projects in Progress (
wwwcf.nlm.nih.gov/hsr_project/home_proj.cfm) (May 2014).
We developed the search strategies for themajor databases with the
help of theCochrane StrokeGroupTrials SearchCo-ordinator and
adapted the MEDLINE search strategy for the other databases.
Searching other resources
In order to identify further published, unpublished and ongoing
trials, we checked reference lists, used the Web of Science Cited
Reference Search for forward tracking of included trials and con-
tacted experts.
Data collection and analysis
Selection of studies
For the 2008 review, all titles and abstracts from each search were
scrutinised for relevance by one of the four previous review au-
thors (GM, EK, LS, AP) who performed the search and excluded
obviously irrelevant studies. Full texts were obtained for poten-
tially relevant studies and a secondary review author scrutinised
these full texts and determined whether they fulfilled the inclusion
criteria (GM scrutinised studies identified by EK, EK scrutinised
studies identified by GM, AP scrutinised studies identified by LS
and LS scrutinised studies identified by AP).
For the current review, one review author (SW) scrutinised all titles
and abstracts from the electronic search (published since Febru-
ary 2008) for relevance. Four other review authors (HYC, EC,
MK, GM) scrutinised all these titles and abstracts independently
from SW: HYC screened studies from MEDLINE, EMBASE,
PsycINFO, AMED, CINAHL, CENTRAL, ProQuest Disserta-
tions and Theses Database, PEDro and British Nursing Index; EC
screened studies from PsycBITE, ISRCTN, Stroke Trials Registry
and Health Service Research Projects in Progress; MK screened
studies from Trials Central; and GM screened studies from the
Cochrane Stroke Trial Register. We excluded obviously irrelevant
citations and obtained full references for potentially relevant stud-
ies. Three review authors (SW, HYC, MK) each independently
read all full texts and determined whether the study fulfilled the
inclusion criteria (for studies published in Chinese, SW and HYC
independently applied the inclusion criteria; for studies published
in Russian, MK applied the inclusion criteria and discussed with
SW). We resolved any discrepancies about whether or not a study
fulfilled the inclusion criteria through discussion.
Data extraction and management
Two review authors (SW,HYC) independently extracted data from
the included trials and recorded the information on a data extrac-
tion form. Another review author (MK) extracted the data for one
trial published in Russian. We collected information about the
study setting, the methodological design (randomisation; alloca-
tion concealment; blinding of participants, researchers and out-
come assessors; and intention-to-treat analysis), the numbers of
participants at recruitment and at the end of the study, the char-
acteristics of participants (age, sex, time since stroke onset, patho-
logical subtypes and severity of stroke), the treatment and control
interventions (type of intervention, dose/intensity, frequency and
duration), the primary and secondary outcome measures (meth-
ods and time of assessment), the criteria and assessment methods
of fatigue at baseline and follow-up, and the results of each assess-
ment. We contacted trial investigators to request additional infor-
mation that we thought relevant but which had not been reported
in the publication.
Assessment of risk of bias in included studies
Two review authors (SW, HYC) independently documented the
methodological quality of the included trials for the following
quality criteria: allocation concealment, blinding of outcome as-
sessors and intention-to-treat analysis. This was done by one re-
view author (MK) for the trial published in Russian. We used the
Cochrane criteria and ’Risk of bias’ tool to assess the methodolog-
ical quality (Higgins 2011).
For allocation concealment, we distinguished between trials that
were adequately concealed (e.g. central randomisation at a site re-
mote from the study, computerised allocation in which records are
in a locked readable file that can be assessed only after entering par-
ticipant details, or the drawing of opaque envelopes), inadequately
concealed (e.g. open list or table of random numbers, open com-
puter systems or drawing of non-opaque envelopes), and where
concealment was unclear (e.g. no information in the report and
trial investigators did not respond to our request or were unable
to provide it).
For blinding of outcome assessors, we distinguished between trials
in which the main outcome was measured by an assessor who was
blind to treatment allocation, and trials in which it was measured
by a non-blinded assessor. For trials where the main outcome was
measured by the participants themselves, we distinguishedwhether
or not the participants were aware of their allocation.
We defined ’intention-to-treat’ as present if two criteria were ful-
filled:
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• all participants were analysed in the groups to which they
were randomised regardless of which (or how much) treatment
they actually received, and regardless of other protocol
irregularities, such as ineligibility; and
• all participants were included regardless of whether their
outcomes were actually collected.
For trials that did not fulfil these two criteria, we determined
whether an ’available-case analysis’ or a ’treatment-received analy-
sis’ had been performed. If, in a trial, outcome data of some par-
ticipants were not available (e.g. due to drop-out or death) and the
investigators only reported available data, we defined it as ’avail-
able-case analysis’. If, in a trial, some participants randomised to
one group ended up in another group and the investigators re-
ported outcome data based on the grouping at the end of study,
we defined it as ’treatment-received analysis’.
Measures of treatment effect
We calculated standardised mean differences (SMDs) and relevant
95% confidence intervals (CIs) for continuous outcomes (i.e. fa-
tigue scores after treatment) and risk ratios (RRs) and relevant
95% CI for dichotomous outcomes (i.e. presence or absence of
fatigue). If there were fatigue scales where the score decreases as
fatigue increases, we multiplied outcomes of these scales by -1.
For trials reporting both dichotomous and continuous outcomes
of fatigue, we collected data for both types of measures.
Assessment of heterogeneity
We assessed heterogeneity between trials and between pre-speci-
fied subgroups. We determined statistical significance of hetero-
geneity based on the statistic with Chi2 distribution with k - 1 de-
grees of freedom (df; where k was the number of trials or number
of subgroups). We quantified heterogeneity using the I2 statistic,
which describes the proportion of total variance across trials that
is attributed to heterogeneity.
Assessment of reporting biases
We had intended to explore publication bias using a funnel plot.
However, this was not done because, according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
“tests for funnel plot asymmetry should be used only when there
are at least 10 studies included in themeta-analysis”. In our review,
there were only six trials in the meta-analysis.
Data synthesis
We performed separate analyses for trials primarily intended to
treat PSF, for trials primarily intended to prevent PSF, and for
trials not primarily targeting PSF, because the key characteristic
of their participants (i.e. whether they had fatigue at recruitment)
was different.
Trials primarily intended to treat post-stroke fatigue
We performed separate analyses for trials that compared the in-
tervention(s) with a control (where placebo, usual medical care or
wait-list was used as control) and for trials that compared different
interventions without a control.
Trials with a control arm
We performed separate analyses for continuous outcomes and for
dichotomous outcomes of fatigue. For either type of outcome,
where data were suitable, we performedmeta-analyses using a ran-
dom-effects model in Review Manager 5 (RevMan 2014).
• If a trial compared interventions of different doses versus
control (e.g. high-intensity exercise versus low-intensity exercise
versus control), we combined the results of the various active
treatment arms using a random-effects model, or where that was
not possible, we divided the numbers of participants in the
control group into several parts, one to go with each active arm,
so that participants were not double counted.
• If a trial compared two or more different interventions
versus control, we divided the numbers of participants in the
control group into several parts, one to go with each active arm.
• If a trial assessed outcomes at multiple time points (e.g.
immediately after treatment and at six-month follow-up), we
performed separate analyses for outcomes assessed at each time
point.
Trials without a control arm
For trials without a control arm, we had intended to perform the
same analyses as we did for trials with a control arm. However, we
did not perform a meta-analysis because no two trials compared a
same pair of interventions; instead, we calculated individual mean
difference (MD) or RR for each trial, which would indicate the
comparative efficacy of one intervention over the other. Here we
used MD rather than SMD for continuous outcomes because
SMDwas used for the pooling of results from trials using different
scales for the same outcome, but for individual trials MD was
preferable because it was more interpretable.
Trials primarily intended to prevent post-stroke fatigue
We had intended to perform the same analyses for this group of
trials as we did for the trials primarily intended to treat PSF, but
we identified no trials for inclusion in this group.
Trials not primarily intended to treat or prevent post-stroke
fatigue
Wehad intended to perform the same analyses for this group of tri-
als as we did for the trials primarily intended to treat PSF.However,
the data were too diverse across trials to be pooled, as they were
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different in all four aspects of PICO (studied populations, treat-
ment and control interventions and outcome measures). There-
fore, we calculated theMD or RR for each trial and reported them
individually.
Subgroup analysis and investigation of heterogeneity
We had intended to explore clinical heterogeneity by subgroup
analyses for the primary outcome, that is, severity or proportion
of fatigue (Deeks 2001). These were:
• type of interventions;
• source of participants (i.e. inpatients versus community
patients);
• time of recruitment since stroke onset;
• amount of treatment (i.e. dose/intensity and duration).
We had intended to perform the subgroup analysis for different
types of interventions. However, trials in the meta-analysis each
had used a different intervention. Thus, we broadly categorised
these interventions into ’pharmacological interventions’ and ’non-
pharmacological interventions’ and performed a subgroup analysis
to investigate whether one group of interventions was superior to
the other.
We did not perform other subgroup analyses (i.e. for source of
participants, time since stroke and amount of treatment). This
is because these subgroups were pre-specified to investigate the
contribution of these clinical characteristics to heterogeneity un-
der the same type of intervention (e.g. antidepressant, cognitive
behavioural therapy or physical exercise), but trials included in
the meta-analysis had each used a different intervention, thus, we
could not perform further subgroup analyses under the individual
type of interventions.
Sensitivity analysis
We explored methodological heterogeneity by sensitivity analyses.
• Allocation concealment: with analysis limited to trials with
adequate allocation concealment.
• Blinding of outcome assessors: with analysis limited to trials
with blinding of outcome assessors.
• Intention-to-treat analysis: with analysis limited to trials
with intention-to-treat analyses.
• We performed one post-hoc sensitivity analysis by
excluding one trial in which the baseline fatigue scores were not
comparable between groups.
• We performed one post-hoc sensitivity analysis by excluding
one comparison that was a visual outlier in the forest plot.
For each sensitivity analysis, we compared the pooled effect size
with the summary effect size of all included trials, using a Z-test
(Borenstein 2009).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Figure 1 summarises the process for electronic searches and study
selection.
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Figure 1. Diagram of electronic search and study selection.
For the 2008 review, we identified 4742 citations and obtained
full texts for 29 potentially eligible studies, of which three trials
were eligible (Choi-Kwon 2007; Lorig 2001; Ogden 1998). We
also identified two ongoing trials, both of which were published
by the time of the current review (Brown 2013; Zedlitz 2012).We
identified these two trials in the 2014 search and included them
in the current review.
For the current review, we searched trials published after 2008
and identified 6839 unique citations from electronic databases
and 909 records from ongoing trials registers. We obtained full
texts for 29 published studies and relevant information for nine
ongoing trials. We included nine new trials (of which two were
ongoing trials in the 2008 review) and nine new ongoing trials
that met the inclusion criteria. Together with the three trials iden-
tified in the 2008 review, we included 12 published trials (Brown
2013; Choi-Kwon 2007; Clarke 2012; Guo 2012; Gurak 2005;
Johansson 2012a; Johansson 2012b; Karaiskos 2012; Lorig 2001;
Ogden 1998; Zedlitz 2012; Zhou 2010), and nine ongoing tri-
als (AFFINITY 2013; Chuang 2013; EFFECTS 2014; FOCUS
2012; Liu 2012; MacKay-Lyons 2012; Michael 2008; Overgaard
2012; Vanroy 2010).
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Included studies
Completed trials
Among the 12 included trials (703 participants), eight trials (455
participants) were primarily intended to treat PSF (i.e. where
the presence of fatigue was an inclusion criterion for recruit-
ment) (Choi-Kwon 2007; Clarke 2012; Guo 2012; Gurak 2005;
Johansson 2012a; Johansson 2012b; Zedlitz 2012; Zhou 2010),
no trial was primarily intended to prevent fatigue after stroke and
the other four trials (248 participants) did not primarily target
PSF but reported fatigue as an outcome (Brown 2013; Karaiskos
2012; Ogden 1998; Lorig 2001).
Trials primarily intended to treat post-stroke fatigue
Participant characteristics
• Sex and age: All eight trials (455 participants) recruited
adults of both sexes with the male proportion ranging from 33%
(Gurak 2005) to 80% (Choi-Kwon 2007) and the mean age
ranging from 50 years (Johansson 2012a) to 72 years (Clarke
2012), except for one trial, which recruited mixed populations of
people with stroke (16 participants) or traumatic brain injury
(10 participants) but did not report these demographics for the
subgroup of people with stroke separately (Johansson 2012b).
• Subtype of stroke: Five trials recruited people with
ischaemic stroke and haemorrhagic stroke (Choi-Kwon 2007;
Clarke 2012; Johansson 2012a; Johansson 2012b; Zedlitz 2012),
and three trials recruited only people with ischaemic stroke (Guo
2012; Gurak 2005; Zhou 2010).
• Source of participants: Six trials recruited community-
dwelling people with stroke (Choi-Kwon 2007; Clarke 2012;
Gurak 2005; Johansson 2012a; Johansson 2012b; Zedlitz 2012),
one trial recruited inpatients (Guo 2012), and one trial recruited
both inpatients and outpatients (Zhou 2010).
• Recruitment time window: Three trials recruited people
who were at least three months after stroke onset (Choi-Kwon
2007; Clarke 2012; Gurak 2005), one trial more than four
months after stroke (Zedlitz 2012), two trials more than one year
after stroke (Johansson 2012a; Johansson 2012b), one trial
within six months of stroke (Guo 2012), and one trial with
people at a mean of six months and no more than three years
after stroke (Zhou 2010).
• Measures for baseline fatigue: Different diagnostic criteria
of fatigue were used at recruitment, which included the self
reported experience of fatigue by participants (Choi-Kwon
2007), a mean score of the FSS of 4 or more (Clarke 2012), the
Traditional Chinese Medicine (TCM) diagnostic criteria for Qi-
deficiency (i.e. fatigue in Chinese culture) (Guo 2012), a score of
the Multidimensional Fatigue Inventory-20 (MFI-20, cut-off
score not reported) (Gurak 2005), a total score of the Mental
Fatigue Scale (MFS) of 10 or more (Johansson 2012a; Johansson
2012b), a total score of the Checklist Individual Strength-fatigue
subscale (CIS-f ) of 40 or more (Zedlitz 2012), and a total score
of the energy subscale of the Stroke Specific Quality of Life
(SSQOL-energy) of 12 or less (Zhou 2010).
Treatment and control interventions
Four trials investigated pharmacological interventions and the
other four trials investigated non-pharmacological interventions.
Table 1 summarises details of treatment and control interventions
for each individual trials.
Outcome measures
Table 1 summarises outcome measures and time of assessment for
each individual trial.
• Methods of outcome assessment: All eight trials reported
fatigue scores in each group after treatment (continuous outcome
of fatigue): three trials used the FSS (Choi-Kwon 2007; Clarke
2012; Guo 2012), two trials used the MFS (Johansson 2012a;
Johansson 2012b), one trial used the MFI-20 (Gurak 2005), one
trial used the CIS-f (Zedlitz 2012), and one trial used the
SSQOL-energy (Zhou 2010). All these scales, except for the
SSQOL-energy, increase as fatigue severity increases. Two trials
reported the numbers/proportions of people with stroke with
PSF after treatment (dichotomous outcome of fatigue): one trial
used the self report of subjective experience of fatigue by
participants (Choi-Kwon 2007), and the other trial used a cut-
off score of 12 on the SSQOL-energy as the criterion for the
presence of fatigue (Zhou 2010).
• Time of outcome assessment: All eight trials assessed fatigue
outcomes immediately after the end of treatment. In addition,
four trials assessed the presence or severity of fatigue at a later
follow-up point: one trial at two months after the end of
treatment (Zhou 2010), two trials at three months after the end
of treatment (Choi-Kwon 2007; Clarke 2012), and the other
study at six months after the end of treatment (Zedlitz 2012).
Trials primarily intended to prevent post-stroke fatigue
We identified no trials primarily intended to prevent PSF.
Trials not primarily intended to treat or prevent post-stroke
fatigue
Four trials (248 participants) did not primarily target PSF but
primarily intended to investigate the efficacy of interventions on
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the recovery of other symptoms after stroke. These trials reported
fatigue as a secondary outcome.
Intervention compared with control
Three trials compared intervention with control.
• Brown 2013 assessed the feasibility of continuous positive
airway pressure (CPAP) therapy for sleep apnoea in people with
ischaemic stroke. Thirty-two people with stroke who had a
positive result on the test for sleep apnoea were randomised to
either the active CPAP group or the sham CPAP group.
Participants were given a device of active or sham CPAP for
home use. Nineteen participants completed the three-month
treatment. The primary outcome was the self reported usage of
CPAP by participants. Fatigue was measured using the FSS as a
secondary outcome by the end of the three-month treatment.
We calculated the MD for post-treatment fatigue scores between
the active CPAP group and the sham CPAP group.
• Lorig 2001 evaluated a Chronic Disease Self-Management
Programme (CDSMP) on health status, healthcare utilisation
and self efficacy outcomes in people with stroke, heart disease,
lung disease or arthritis. In total, 1140 community-dwelling
people were recruited, of which 125 had stroke. Of these 125
people with stroke, 67 were allocated to the CDSMP group and
58 to the wait-list control group. Participants in the CDSMP
group were immediately offered a manual of programme content
and received seven consecutive weekly sessions (peer-taught
sessions, 2.5 hours for each session). Participants in the wait-list
group were offered the manual and CDSMP six months after
randomisation. Primary outcomes were health behaviours, health
status and health service utilisation. Fatigue was measured using
the energy/fatigue scale from the long-form Medical Outcomes
Study as a secondary outcome. Outcomes were collected at
baseline, six months, one year and two years after randomisation.
The trial investigators did not report results separately for the
different diseases, but they provided unpublished data for the
subgroup of 125 people with stroke at the six-month follow-up.
However, the investigators did not provide data of post-
treatment scores but only the changes of scores from baseline to
after treatment. We calculated the MD for the changes of scores
between the CDSMP group and the wait-list group.
• Ogden 1998 assessed the efficacy of tirilazad mesylate (a
hypothesised neuroprotective agent) on recovery from SAH.
Thirty-one women were randomised to receive either tirilazad
mesylate (150 mg/100 mL) or placebo (100 mL) for 10
consecutive days after SAH. Eighteen women were interviewed
three months later and were asked whether they had experienced
fatigue that was much worse than before their SAH. If they
answered ’yes’ then the interviewer explored this with further
questioning and participants were asked to provide specific
examples. Participants’ responses to questioning were analysed as
a ’yes or no’ to debilitating fatigue based on the subjective
opinion of the interviewer. We calculated the RR for the risk of
participants having fatigue after treatment between the tirilazad
group and the placebo group.
Different interventions compared without a control
One trial compared different interventions without a control.
• Karaiskos 2012 investigated the efficacy of three
antidepressants for treating depression in people with ischaemic
or haemorrhagic stroke. Sixty people with a clinical diagnosis of
depression after stroke were randomised to one of three groups
for antidepressive treatment: duloxetine (60 to 120 mg/day, for
three months), citalopram (20 to 40 mg/day, for three months)
or sertraline (50 to 200 mg/day, for three months). The primary
aim of this trial was to investigate the effects of these
antidepressants on depression and anxiety. Fatigue was measured
using the FSS as a secondary outcome at one month, two
months and three months after the start of treatment. We
calculated the MDs for FSS at the end of three-month treatment
between the duloxetine group and the citalopram group,
between the duloxetine group and the sertraline group, and
between the citalopram group and the sertraline group.
Ongoing trials
The two ongoing trials identified in the previous review, Brown
2013 andZedlitz 2012, were completed and published by the time
of our search in 2014 and are discussed in the Included studies
section in this review. We identified a further nine ongoing trials
in the 2014 search.
Three trials were primarily intended to treat PSF.
• Chuang 2013 (estimated enrolment: 160 participants)
investigates the efficacy of a combined therapy of functional
electrical stimulation and graded treadmill training (one hour
daily, three days per week for four weeks) versus conventional
rehabilitation on fatigue and shoulder pain after stroke. The
inclusion criteria require participants to be at least six months
after stroke and have hemiplegic shoulder pain and PSF within
the past seven days before assessment. The primary outcome is a
vertical numerical rating scale with face rating scale for fatigue
and pain at the end of treatment.
• Liu 2012 (90 participants) investigates the efficacy of
Astragalus membranaceus (a Chinese herb, 2.8 g three times per
day, treatment duration unknown) versus placebo (2.8 g three
times per day, treatment duration unknown) on PSF. The
inclusion criteria require participants to be at least three months
after stroke and have fatigue based on a screening scale (methods
unknown). The primary outcome is the Brief Fatigue Inventory
at two years after treatment.
• Overgaard 2012 (128 participants) investigates the efficacy
of modafinil (a wakefulness promoting agent, 400 mg once daily
for three months) versus placebo (400 mg once daily for three
11Interventions for post-stroke fatigue (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
months) on PSF. The inclusion criteria require participants to be
within 14 days of stroke onset and have fatigue according to the
MFI-20. The primary outcome is the total score of MFI-20 at
the end of the three-month treatment period.
Three trials are investigating the efficacy of physical training on
functional outcomes of stroke, where fatigue is measured as a sec-
ondary outcome.
• MacKay-Lyons 2012 (20 participants) investigates the
efficacy of aerobic exercise or cognitive training, or both, on
cognition after stroke. People who are at least six months after
stroke are randomised to one of the four arms for a six-week
treatment: aerobic training group, cognitive training group,
aerobic plus cognitive training group and control group. Fatigue
is assessed using the FSS at 10-week follow-up.
• Michael 2008 (54 participants) investigates the efficacy of
adaptive physical activity (APA) on physical fitness and quality of
life of people with stroke. People who are at least six months after
an ischaemic stroke or who are one year after a haemorrhagic
stroke and with residual hemiparetic gait deficits are randomised
to one of the three arms for a six-month treatment: APA group,
APA plus progressive treadmill walking group and home exercise
group. Fatigue is assessed by psychosocial questionnaires as a
secondary outcome at baseline, three months, six months and
nine months after the beginning of the treatment.
• Vanroy 2010 (50 participants) investigates the efficacy of
aerobic exercise on aerobic capacity and daily functioning in
people with stroke. People who are within six weeks after stroke
onset are randomised to either an aerobic exercise group or a
passive mobilisation group for a 12-week treatment. Fatigue is
assessed at baseline, after 12 weeks’ treatment, six months, one
year and two years after baseline (assessment methods unknown).
This trial has been completed but is not yet published.
Three parallel trials investigate the efficacy of fluoxetine on recov-
ery of stroke and assess fatigue as a secondary outcome.
• FOCUS 2012 (3000 participants).
• AFFINITY 2013 (1600 participants).
• EFFECTS 2014 (1500 participants).
These three trials share the same core protocol, which recruits
people who are between two and 15 days after stroke onset and
randomise them to either the fluoxetine group (20 mg daily orally
for six months) or the placebo group (20 mg daily orally for six
months). The primary outcome is the mRS at six months after
recruitment. Fatigue is a secondary outcome assessed by the vitality
subscale of Short Form-36 at six months and 12 months after
recruitment.
Excluded studies
In the 2008 review, we excluded two trials because one had no
fatigue-related outcomes (Allison 2007), and in one fatigue was
not a measure for therapeutic effect (Underwood 2006).We iden-
tified a further nine trials from the 2014 search but we excluded
them after full-text screening: in two trials, fatigue was measured
to assess whether participants were too tired after using the inter-
vention rather than to test the therapeutic effect on fatigue (Cruz
2013; Lin 2013); three ongoing trials were specifically targeting
PSF but were excluded because they had only a single treatment
group without a control arm (Feys 2013; Kirkevold 2012; Wu
2014b); two trials did not use randomisation (Kim 2012; Sianni
2008); one trial compared people with multiple sclerosis with peo-
ple with stroke but did not have a control group for people with
stroke (Brioschi 2009); and one trial recruited mixed populations
of participants but did not report data for the subgroup of people
with stroke and we could not obtain these data from trial investi-
gators (Robinson 2003).
Risk of bias in included studies
Figure 2 and Figure 3 summarise the risk of bias in all included
trials, irrespective of whether they were primarily intended to treat
or prevent PSF. Reasons or support information for the judgement
are provided in a ’Risk of bias’ table for each trial in Characteristics
of included studies. In this section, we separately summarise the
risk of bias of the eight trials primarily intended to treat PSF and
that of the four trials not primarily intended for PSF.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation concealment (selection bias)
Of the eight trials primarily intended to treat PSF, two trials had
a low risk of bias (Choi-Kwon 2007; Johansson 2012a), one trial
reported the use of ’placebo’ but did not report details of allocation
concealment thus its risk of bias was unclear (Guo 2012), and
the other five trials had a high risk of bias because they did not
use adequate allocation concealment (Clarke 2012; Gurak 2005;
Johansson 2012b; Zedlitz 2012; Zhou 2010).
Of the four trials not primarily intended for PSF, two trials had
a low risk of bias (Brown 2013; Ogden 1998), and the other two
trials had a high risk of bias (Karaiskos 2012; Lorig 2001).
Blinding of outcome assessors (detection bias)
Of the eight trials primarily intended to treat PSF, five trials used
adequate strategies for outcome assessor blinding and thus had
a low risk of bias (Choi-Kwon 2007; Clarke 2012; Guo 2012;
Johansson 2012a; Zedlitz 2012), and the other three trials did not
report sufficient information to permit this judgement thus the
risk was unclear (Gurak 2005; Johansson 2012b; Zhou 2010).
Of the four trials not primarily intended for PSF, two trials had a
low risk of bias (Brown 2013; Ogden 1998), and the risk in other
two trials was unclear (Karaiskos 2012; Lorig 2001).
Intention-to-treat analysis (attrition bias)
Of the eight trials primarily intended to treat PSF, two trials per-
formed intention-to-treat analysis (low risk) (Choi-Kwon 2007;
Zedlitz 2012), three trials had the same numbers of participants at
the end of trial as at randomisation (low risk) (Guo 2012; Gurak
2005; Zhou 2010), and the other three trials had drop-outs and
used the available-case analysis (high risk) (Clarke 2012; Johansson
2012a; Johansson 2012b).
Of the four trials not primarily intended for PSF, one study had
the same number of participants at the end of trial as that at
randomisation (low risk) (Karaiskos 2012), and the other three
trials had drop-outs and used the available-case analysis (high risk)
(Brown 2013; Lorig 2001; Ogden 1998).
Effects of interventions
See: Summary of findings for the main comparison
Interventions specifically targeting the treatment of post-stroke
fatigue; Summary of findings 2 Interventions not specifically
targeting post-stroke fatigue
Trials primarily intended to treat post-stroke fatigue
Eight trials (455 participants) were primarily intended to treat
PSF, of which six trials compared the intervention(s) with con-
trol (where the control was placebo, usual medical care or wait-
list) (Choi-Kwon 2007; Clarke 2012; Guo 2012; Gurak 2005;
Johansson 2012a; Johansson 2012b), and the other two trials com-
pared different potentially active interventions without a control
arm (Zedlitz 2012; Zhou 2010) (Table 1).
Trials with a control arm (intervention versus control)
Of the six trials (244 participants) that had a control arm (Choi-
Kwon 2007; Clarke 2012; Guo 2012; Gurak 2005; Johansson
2012a; Johansson 2012b), one trial compared two potentially ac-
tive interventions with a control (Guo 2012). For this trial, we
divided the number of participants in the control group to two
equal-size groups so that there were two comparisons each with
a treatment group and a control group. Thus, there were seven
comparisons with 244 participants.
Continuous outcomes
Summary meta-analysis
All of these six trials (seven comparisons with 244 participants)
reported continuous measures of fatigue after treatment. Fatigue
severity was lower in the intervention group compared with the
control group (pooled SMD -1.07, 95% CI -1.93 to -0.21), with
significant heterogeneity between trials (I2 = 87%, df = 6, P value
< 0.00001 for heterogeneity) (Analysis 1.1).
Subgroup analysis
We had intended to perform the subgroup analysis for different
types of interventions (e.g. antidepressants, psychological therapy
and physical training), but this was not achieved because each of
the seven comparisons used a different treatment intervention.
Thus, we could only broadly categorise these interventions to
two groups: ’pharmacological interventions’ and ’non-pharmaco-
logical interventions’. Although there was no significant hetero-
geneity between these two subgroups (I2 = 0%, df = 1, P value
= 0.42, indicating no statistically significant difference of effect
sizes between two subgroups), only pharmacological interventions
showed a marginally significant effect on reducing PSF (five com-
parisons, 209 participants, pooled SMD -1.23, 95% CI -2.40 to
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-0.06; with significant heterogeneity: I2 = 91%, df = 4, P value
< 0.00001) while non-pharmacological interventions showed no
statistically significant effect (two comparisons, 35 participants,
pooled SMD -0.68, 95% CI -1.37 to 0.02; with no significant
heterogeneity: I2 = 0%, df = 1, P value = 0.42) (Analysis 1.1).
Sensitivity analysis
• Trials using adequate allocation concealment
◦ Two trials (two comparisons, 89 participants) reported
adequate strategies for allocation concealment (Choi-Kwon
2007; Johansson 2012a), of which interventions showed no
significant effect on PSF (pooled SMD -0.38, 95% CI -0.80 to
0.04; with no significant heterogeneity: I2 = 0%, df = 1, P value
= 0.90) (Analysis 1.2).
• Trials using adequate blinding of outcome assessors
◦ Four trials (five comparisons, 198 participants)
reported adequate strategies for blinding of outcome assessors
(Choi-Kwon 2007; Clarke 2012; Guo 2012; Johansson 2012a),
of which interventions showed no significant effect on PSF
(pooled SMD -1.10, 95% CI -2.31 to 0.11; with significant
heterogeneity: I2 = 91%, df = 4, P value < 0.00001) (Analysis
1.2).
• Trials using intention-to-treat analysis
◦ Three trials (four comparisons, 203 participants) used
intention-to-treat analysis or had no participant lost to follow-up
(Choi-Kwon 2007; Guo 2012; Gurak 2005), of which the
intervention showed a beneficial effect over the control (pooled
SMD -1.41, 95% CI -2.73 to -0.09; with significant
heterogeneity: I2 = 93%, df = 3, P value < 0.00001) (Analysis
1.2). This pooled SMD was not significantly different (P value =
0.67) from the summary SMD of all seven comparisons (pooled
SMD -1.07, 95% CI -1.93 to -0.21).
• Trials with no significant difference in baseline fatigue
scores between groups
◦ Fatigue scores at baseline in one trial were significantly
higher in the control group than the treatment group
(Choi-Kwon 2007), so we performed a post-hoc sensitivity
analysis by excluding this trial. The pooled SMD of the
remaining five trials (six comparisons, 161 participants) was -
1.22 (95% CI -2.34 to -0.09; with significant heterogeneity: I2 =
88%, df = 5, P value < 0.00001) (Analysis 1.2), which was not
significantly different (P value = 0.84) from the summary SMD
of all seven comparisons (pooled SMD -1.07, 95% CI -1.93 to -
0.21).
• Excluding the visual outlier in the forest plot
◦ One comparison in Guo 2012, a combination of oral
and intravenous Chinese herbs versus placebo Chinese herbs
(SMD -4.35, 95% CI -5.48 to -3.22), appeared as an outlier in
the forest plot (Analysis 1.1). After excluding this comparison
(45 participants), the pooled SMD of the remaining six
comparisons (199 participants) was -0.49 (95% CI -0.78 to -
0.20; with no significant heterogeneity: I2 = 0%, df = 5, P value
= 0.52) (Analysis 1.2), which was not significantly different (P
value = 0.21) from the summary SMD of all seven comparisons
(pooled SMD -1.07, 95% CI -1.93 to -0.21).
Analysis of individual trials
For the seven comparisons in the meta-analysis, Figure 4 presents
the treatment interventions of each individual trial and a visual
comparison of their effect sizes.
Figure 4. Effects of interventions on fatigue severity at the end of treatment and at three-month follow-up.
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For the two trials that assessed fatigue at three months after the
end of treatment, we also calculated the SMDs for these follow-
up outcomes. Figure 4 presents the results.
Dichotomous outcomes
Of the six trials (seven comparisons) that compared the interven-
tion with control, only one trial (83 participants) reported the
number/proportion of participants with PSF after treatment (di-
chotomous outcomes of fatigue) (Choi-Kwon 2007). There was
no significant difference in proportions of participants with PSF
between the fluoxetine group and the placebo group at baseline
(100% versus 100%), at the end of treatment (82% versus 93%,
RR 0.89, 95% CI 0.75 to 1.05, Analysis 1.3), or at three months
after the end of treatment (85% versus 93%, RR 0.91, 95% CI
0.78 to 1.07).
Trials without a control arm (comparison between different
interventions)
Two trials compared different potentially active interventions
without a control arm. Because these two pairs of comparisons
were different (also because they reported different types of out-
comes), we did not perform a meta-analysis, but calculated indi-
vidual MD or RR for each trial.
Zedlitz 2012 (83 participants) reported the continuous outcomes
of fatigue after treatment. Fatigue scores were not significantly
different between the COgnitive and GRaded Activity Training
(COGRAT) group and the cognitive therapy group either at the
end of treatment (for CIS-f: MD 0.80, 95% CI -3.63 to 5.23; for
Self-Observation List-fatigue subscale (SOL-f ): MD -0.30, 95%
CI -1.35 to 0.75) or at six months after the end of treatment (for
CIS-f: MD -2.00, 95% CI -6.74 to 2.74; for SOL-f: MD -0.50,
95% CI -1.64 to 0.64).
Zhou 2010 (128participants) reported both continuous outcomes
and dichotomous outcomes of fatigue after treatment. Trial in-
vestigators reported that scores of SSQOL-energy after treatment
were significantly higher (indicating better outcome) in the elec-
troacupuncture plus cupping group than the medication group
(P value < 0.05). These scores were presented graphically but raw
data were not reported and we could not obtain these data from
trial investigators, thus we did not calculate an MD for this trial.
Twenty-two participants in the electroacupuncture plus cupping
group and 41 participants in the medication group had PSF at
the end of treatment (34% versus 64%, RR 0.54, 95% CI 0.37 to
0.79), and 30 participants in the electroacupuncture plus cupping
group and 52 participants in themedication group had PSF at two
months after the end of treatment (47% versus 81%, RR 0.58,
95% CI 0.43 to 0.77).
Secondary outcomes
Three trials assessed health-related quality of life (Clarke 2012;
Guo 2012; Zedlitz 2012), and one trial assessed disability and de-
pendence (Clarke 2012). No trial reported death or cost-effective-
ness. Here we present the results of these outcomes reported by
the trial investigators.
Clarke 2012 reported a significant improvement in Short Form-
36 social functioning for both groups (P value = 0.03) but there
was no difference between groups (P value = 0.20). There was no
significant change from baseline to post-treatment assessment in
the other subscales of Short Form-36, the Barthel Index or the
mRS, and none of the changes were significantly different between
groups.
Guo 2012 reported that the total score of Stroke Specific Quality
of Life after treatment was significantly higher in the TCM (a
combination of Chinese herbs) group than that in the citicoline
group (P value < 0.01) and the placebo group (P value < 0.01).
Zedlitz 2012 reported a significant reduction of scores of Stroke-
adapted Sickness Impact Profile-30 from baseline to post-treat-
ment assessment (P value = 0.002), but this change was not sig-
nificant between groups (P value > 0.1).
Trials primarily intended to prevent post-stroke
fatigue
We identified no trials that were primarily intended to prevent
PSF.
Trials not primarily intended to treat or prevent post-
stroke fatigue
We identified four trials that were not primarily intended to treat
or prevent PSF. Three trials reported continuous outcomes and
one reported dichotomous outcomes of fatigue after treatment.
We did not pool results from these trials because they had sub-
stantial differences in the studied populations, treatment and con-
trol interventions, and outcome measures. Instead, we calculated
effect sizes for each of these trials and present the individual result
in Table 2. None of these interventions showed any benefit on
reducing fatigue in people with stroke.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Interventions not specifically targeting post-stroke fatigue, compared with compared with placebo, usual medical care or wait-list
Patient or population: people with stroke not necessarily having fatigue
Settings: outpatients
Intervention: interventions not specifically targeting fatigue but other symptoms in people with stroke
Comparison: placebo, usual medical care, or wait-list
Outcomes Illustrative comparative risks (95% CI) Relative effect
(MD or RR and 95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Fatigue severity at the end
of treatment (assessed by
Fatigue Severity Scale)
Follow-up: at the end of
treatment
Sham CPAP group: the
mean fatigue score was
2.66 (-0.65 to 5.97)
Active CPAP group: the
mean fatigue score was
3.11 (0.57 to 5.65)
Fatigue severity in the ac-
tive CPAP group was 0.
45 points higher (-0.59 to
1.49 higher) on Fatigue
Severity Scale, but this






Changes of fatigue scores





Follow-up: at the end of
treatment
Placebo group: the mean
energy score after treat-
ment was 0.246 points
lower (-0.924 to 1.416)
than baseline (i.e. fatigue
severity increased by 0.
246 points)
CDSMP group: the mean
energy score after treat-
ment was 0.087 points
lower (-1.849 to 2.023)
than baseline (i.e. fatigue
severity increased by 0.
087 points)
The increase of fatigue
severity in the CDSMP
group was 0.16 points
less (-0.44 to 0.12 less)
on the energy/fatigue
scale, but this difference




Higher energy score indi-
cates lower fatigue sever-
ity; decrease of energy
score indicates increase
of fatigue severity; the
greater decrease of en-
ergy score indicates the
greater increase of fatigue
severity
Proportion of participants
with fatigue after treat-
ment (assessed by the
self report by partici-
pants)
Follow-up: at the end of
Placebo group: the pro-
portion of participants
with fatigue was 60% (9/
15)
Tirilazad mesylate group:
the proportion of partic-
ipants with fatigue was
25% (4/16)
The risk participants with
fatigue in tirilazad group
was 47% of that in the
control group (RR 0.42,
95% CI 0.16 to 1.07), but





















































































CDSMP: Chronic Disease Self-Management Programme
CI: confidence interval
CPAP: continuous positive airway pressure
MD: mean difference
RR: risk ratio
1. This was a small trial (imprecision) with a significant attrition bias (risk of bias), as 13 out of 32 participants dropped out and the
investigators only reported data for the remaining 19 participants. The intervention (CPAP) was primarily aimed to treat sleep apnoea,
which showed no effect on either scores of sleep apnoea or scores of fatigue. Together with the significant attrition bias, we have no
confidence in concluding whether the intervention was effective or ineffective in treating sleep apnoea, or fatigue, or both (indirectness).
2. This trial had several sources of risks of bias: a) attrition bias (21 out of 125 participants dropped out, 16%); b) performance bias (the
interventions were visibly different to participants); and c) detection bias (no sufficient information to permit judgement on this risk). The
intervention was not specifically designed for people with stroke or to manage fatigue (indirectness).
3. This was a small trial (imprecision) with a significant attrition bias (risk of bias), as 13 out of 31 participants dropped out and the
investigators only reported data for the remaining 18 participants. Fatigue was not measured at baseline, so we do not know specifically
whether this intervention was effective in preventing fatigue in non-fatigued people with stroke or if it was effective in treating fatigue in

















































































D I S C U S S I O N
Summary of main results
We included 12 trials (703 participants) in this review: three trials
identified in the 2008 version and nine additional trials published
since 2008 (two of which were ongoing trials in the 2008 review).
We also identified nine ongoing trials meeting our inclusion cri-
teria. Of the 12 published trials, eight trials primarily intended to
treat PSF, none primarily intended to prevent PSF and the other
four trials did not primarily target PSF. Summary of findings for
the main comparison and Summary of findings 2 present the key
findings from these trials.
Of the eight trials primarily intended to treat PSF, four trials inves-
tigated pharmacological interventions and the other four investi-
gated non-pharmacological interventions.Meta-analysis indicated
a statistically significant benefit of these interventions on treating
PSF. However, the benefit was not seen in trials with a low risk
of bias. Subgroup analysis further demonstrated a marginally sta-
tistically significant benefit of pharmacological interventions and
no statistically significant benefit of non-pharmacological inter-
ventions. The identified trials were small and heterogeneous, and
some had a high risk of bias. Of the four trials not primarily in-
tended to treat or prevent PSF, none showed an effect on reducing
fatigue in people with stroke. In summary, there are insufficient
data to draw any firm conclusions about whether or not these in-
terventions were effective, either to treat or prevent PSF.
Antidepressants and other psychostimulants
One previous systematic review found that PSF was associated
with depressive symptoms and this association existed even in peo-
ple with stroke who did not meet clinical criteria for depression
(Wu 2014a). Thus, it is plausible that treatment for depression
may reduce PSF. In addition, small trials found that PSF was as-
sociated with serotonin synthesis (Ormstad 2014). Potential effi-
cacy of psychostimulants in the management of PSF was shown in
non-randomised trials (Brioschi 2009; Kalinski 2008). However,
RCTs identified in the current review found no beneficial effects of
any antidepressants (Choi-Kwon 2007; Karaiskos 2012), or other
psychostimulants (Johansson 2012a), on PSF. It is important to
note that these trials were small, thus may lack the power to detect
the effect. A number of larger trials are ongoing, which may pro-
vide further evidence on the efficacy of psychostimulants on PSF
(AFFINITY 2013; EFFECTS 2014; FOCUS 2012; Overgaard
2012).
Psychological interventions
Although PSF is associated with depressive symptoms and neu-
roendocrine changes, RCTs to date provided no evidence on the
efficacy of psychostimulants. One possible explanation is that PSF
is a complex symptom influenced by amixture of biological, phys-
ical, psychological and behavioural factors and there are interac-
tions between these factors (Wu 2015). Psychological interven-
tions (e.g. cognitive behavioural therapy) targeting these psychobe-
havioural factors are effective in treating fatigue in other condi-
tions (such as cancer (Armes 2007), and chronic fatigue syndrome
(White 2011)), thus might be promising for PSF. However, RCTs
investigating psychological interventions in people with PSF did
not demonstrate whether or not these interventions were effective
due to the limitations in the study design (Clarke 2012; Johansson
2012b; Lorig 2001; Zedlitz 2012). Thus, future studies are ex-
pected to investigate the efficacy of psychological interventions
specially designed for PSF in RCTs with adequate sample sizes and
controlled with usual medical care.
Physical training
Small studies found that PSF was associated with reduced physical
fitness (Lewis 2011), and lower levels of physical activity (Duncan
2015). Furthermore, one study found that PSF was related to
the reduced excitability of the motor cortex (Kuppuswamy 2015).
Physical training after stroke may improve physical fitness and
stimulate cortical excitability, which may help to reduce fatigue.
In this review, we found one trial that reported that cognitive be-
havioural therapy plus graded activity training was more effective
in reducing PSF than cognitive behavioural therapy alone (Zedlitz
2012). However, from this trial we do not know whether the re-
duction of fatigue was a result of the physical training alone or a
combination effect of physical training and cognitive behavioural
therapy. This question may be answered by some ongoing trials
that compare physical training, cognitive training, or both, with a
sham or usual medical care control (Chuang 2013;MacKay-Lyons
2012; Michael 2008; Vanroy 2010).
Traditional Chinese therapies
In this review, we identified two trials which investigated tradi-
tional Chinese therapies for PSF (Guo 2012; Zhou 2010). In gen-
eral, the quality of these trials was low and the components of
these Chinese traditional therapies were complicated. Efficacy of
these interventions should be investigated in future RCTs with
more robust study designs and using adequate controls. Further-
more, since these are complex interventions that have different
components, a pre-specified protocol or regimen of interventions
are needed before starting the trial, and where possible, which
component(s) plays the leading role in therapeutic effect should
be investigated. For example, a randomised, placebo-controlled,
double-blind trial is ongoing to investigate the efficacy of Astra-
galus membranaceus (a Chinese herb) on PSF (Liu 2012).
Other interventions
Vitamin supplementation is potentially effective in some cases
of PSF. One observational study found that fatigue after lacunar
strokes was associated with vitamin B12 deficiency (Huijts 2012).
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There is also a case report of the efficacy of high-dose vitamin B1
in treating fatigue in three people with stroke (Costantini 2014).
One non-randomised trial reported that the antioxidant idebenon
(a synthetic analogous of coenzymeQ10) was effective in theman-
agement of PSF (Bo ko 2013). In this review, we identified one
small trial that found that enerion (a synthetic derivative of vita-
min B1) was effective in reducing PSF (Gurak 2005). However,
this trial was limited by its small sample size of 15 participants in
each group and the high risk of selection bias, thus future trials
are needed. Another two interventions, tirilazad mesylate (Ogden
1998), and CPAP (Brown 2013), had no effect on PSF. However,
neither of these interventions was specifically designed for PSF.
In addition, these two trials were small and both had a high risk
of attrition bias. Thus, the effect of these interventions on PSF is
unknown.
Overall completeness and applicability of
evidence
The inclusion criteria of this review were deliberately broad with
an aim to inform future research. We sought to include trials in
which fatigue was a secondary as well as a primary outcome and the
participants in the included trials did not necessarily have fatigue at
baseline to be eligible for inclusion, because identifying strategies
to prevent (as well as treat) fatigue are important.
We identified five broad categories of interventions particularly
targeting the treatment of PSF, that is, antidepressants and other
psychostimulants, psychological interventions, physical training,
traditional Chinese therapies and other interventions. Generally,
the existing trials provided no evidence on the efficacy of an-
tidepressants on PSF, irrespective of whether the participants met
the criteria of post-stroke depression or not. However, these trials
were small and may, therefore, lack the power to detect significant
effects. Psychological interventions targeting patients’ cognition
and behaviours are feasible in people with stroke but their effi-
cacy should be investigated in future RCTs that compare these in-
terventions with the usual medical care control. Traditional Chi-
nese therapies (including medicine and physical therapy) showed
promising effects on PSF, but the components of each therapywere
complicated and the study quality was poor. Some other interven-
tions showed efficacy on PSF in single small trials, for example
enerion (a compound of vitamin B1) and tirilazad mesylate (a hy-
pothesised neuroprotective agent). In addition, (-)-OSU6162 (a
monoaminergic stabiliser) was tolerable in six people with stroke
patients but had no efficacy on fatigue. These were small trials and
the efficacy of these drugs should be investigated in future RCTs
with an adequate sample size and a robust study design. CPAP,
which was designed for sleep apnoea after stroke, was of no benefit
on reducing either fatigue or sleep apnoea after stroke. This trial
was very small and had significant drop-outs. In addition, we do
not know if other interventions, if effective for sleep disorders, are
helpful to reduce PSF.
There was considerable heterogeneity in the study design of the
included trials. First, the heterogeneity might be attributed to the
different interventions used in different trials. Although we strat-
ified heterogeneity by grouping trials into pharmacological inter-
ventions and non-pharmacological interventions, significant het-
erogeneity remained within the subgroup of pharmacological in-
terventions, where no two trials used a same type of drug. This
means each type of intervention has only been evaluated in one
trial, which limits the generalisability of the findings. Second, het-
erogeneity might also be attributed to the differences in partici-
pant characteristics, with many different criteria used for diagno-
sis of fatigue and also the time window from stroke onset to ran-
domisation ranging from within first few months to several years
after stroke. Given different factors may contribute to fatigue at
different stages of its natural history (Wu 2015), the efficacy of
a specific intervention may be different for people with different
characteristics.
Another important aspect of study design is the sample size re-
quired to detect a clinically significant therapeutic effect. Of the
12 included trials, only six trials (50%) had a sample size of over
50 participants (Choi-Kwon 2007; Guo 2012; Karaiskos 2012;
Lorig 2001; Zedlitz 2012; Zhou 2010), and the largest sample was
128 participants (Zhou 2010). The other six trials each had no
more than 30 participants who completed the trial and were pri-
marily aimed to test the feasibility of the interventions rather than
to investigate efficacy (Brown 2013; Clarke 2012; Gurak 2005;
Johansson 2012a; Johansson 2012b; Ogden 1998). In addition,
none of these 12 trials reported how the sample size was deter-
mined. The small sample sizes might have limited the power to
detect the clinically significant effect.
Adverse effects were not a pre-specified outcome of this review.
Only one included trial specifically investigated adverse effects
(Karaiskos 2012), where nausea, somnolence, insomnia, dizziness,
dry mouth, headache and diarrhoea were reported. There was no
difference between the duloxetine group, the citalopramgroup and
the sertraline group and no participants withdrew from this trial.
In another trial, one participant in the fluoxetine group (a selective
serotonin reuptake inhibitor) and another in the placebo group
withdrew due to the ’side effect’ (Choi-Kwon 2007). Another trial
reported several drop-outs due to the intolerance of the CPAP
device (Brown 2013). Two trials reported medical issues as the
reason for drop-out (Clarke 2012; Ogden 1998), but it is unclear
whether it was related to adverse effects of the intervention. The
other four trials reported drop-outs but did not give the reason
(Johansson 2012a; Johansson 2012b; Lorig 2001; Zedlitz 2012).
In general, no severe adverse effects were reported for the included
interventions.
Quality of the evidence
The included trials were small and heterogeneous, and some of
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them had a high risk of bias. It is difficult to interpret the signifi-
cance of outcomes when there is inadequate concealment of allo-
cation, non-blind assessment or significant drop-outs in several of
the included trials. Although the interventions showed an overall
significant effect on treating PSF, the sensitivity analyses indicated
that, in trials with a low risk of bias, this effect was no longer
significant. In summary, there was no robust evidence to inform
the prevention or treatment of PSF. The efficacy of interventions
should be investigated in future RCTs with a more robust design.
Potential biases in the review process
The identification of all relevant trials might have been con-
founded by a number of factors. We did not search any non-En-
glish databases, thus we only had access to trials that published
their abstracts in English. In addition, for trials measuring fatigue
as a secondary outcome, trial investigatorsmight not have reported
the results of fatigue in the abstract or coded it as a keyword iden-
tifiable for electronic searches. Furthermore, some trials had used
scales of which part of the scale is the valid tool for assessing PSF
(e.g. the vitality subscale of the Short Form-36); for these trials,
if fatigue was not a specific target of the intervention, ’fatigue’ or
its synonyms might not appear in the report, thus we could not
identify such trials through electronic searches. To minimise the
risk of missing relevant studies, we used extensive search strategies
and contacted experts in the field for relevant studies. We would
appreciate if other researchers who have noticed any relevant stud-
ies missing from this review could inform us, so that we can update
our review.
Although two review authors independently extracted the trial
data, for one trial that was published in Russian, only one author (a
native speaker of Russian) extracted the data and assessed the study
quality. To minimise the risk of biased assessment, another review
author reviewed the extracted data and clarified the eligibility with
the Russian-speaking review author.
Agreements and disagreements with other
studies or reviews
As far as we know, there are no other systematic reviews of in-
terventions for PSF. Our review identified a mixture of pharma-
cological and non-pharmacological interventions. Non-pharma-
cological interventions identified in our review were similar to
those identified in a Cochrane Overview of reviews of interven-
tions for fatigue in adults with advanced progressive illness (e.g.
cancer, motor neuron diseases and chronic pulmonary diseases),
which include aerobic exercise, physical training, education pro-
grammes and psychological interventions (Payne 2012). However,
in theCochraneOverview, the pharmacological interventions (e.g.
amantadine and carnitine) were different from the pharmacolog-
ical interventions identified in our review (e.g. antidepressants
and neuroendocrine regulators). A possible explanation is that the
choice of drugs might be relevant or specific to fundamental dis-
eases. Furthermore, we found that psychological interventions or
physical training, or both, for fatigue were feasible in people with
stroke, although their efficacy on PSF should be further investi-
gated. This is consistent with a systematic review of interventions
for chronic fatigue syndrome, where the review authors concluded
that cognitive behavioural therapy and graded exercise therapy
were promising treatment strategies for fatigue (Whiting 2001).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was insufficient evidence on the efficacy of any intervention
for the treatment or prevention of post-stroke fatigue (PSF). Trials
to date have been small and heterogeneous, and some have had a
high risk of bias. Some of the interventions described were feasible
in people with stroke, but their efficacy should be investigated
in randomised controlled trials (RCTs) with more robust study
designs and adequate sample sizes.
Implications for research
Given the high prevalence and distressing consequences of fatigue
following stroke, more research is urgently needed to identify ef-
fective interventions for PSF. The wide range of different interven-
tions identified in this review reflect the uncertainty and complex-
ity of the aetiology and mechanism of PSF. Some pharmacologi-
cal interventions have shown benefit on PSF in small single trials,
but their efficacy should be further investigated in RCTs. Further-
more, given that some studies have found an association between
fatigue and mood disorders and physical fitness, psychological in-
terventions and physical training are promising strategies for the
management of PSF. These interventions have shown feasibility
in people with stroke and their efficacy should be investigated in
future RCTs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brown 2013
Methods Parallel randomised trial
Method of randomisation: randomised stated, method unclear
Method of concealment: used sham control with device of identical appearance of that
for active CPAP
Blinding: double-blind
Analysis: only reported data of participants who had completed the 3-month follow-up
(available-case analysis)
Participants Location: USA
Setting: enrolled from a single centre of inpatient neurology service, the treatment was
conducted in the community
Number of participants: 32 at randomisation (59% male, median unknown), 19 com-
pleted study, case-available analysis for 19 participants
Treatment group: 15 (33% male, median age 61 years, IQR 46 to 76)
Control group: 17 (76% male, median age 74 years, IQR 55 to 81)
Stroke criteria: ischaemic stroke based on accepted clinical criteria
Time since stroke onset at randomisation: median time from stroke onset to CPAP
titration was 4 days
Fatigue criteria: participants did not have to have fatigue to be recruited
Other entry criteria: had sleep apnoea; modified Rankin Scale ≥ 2
Comparability of groups: unclear
Interventions Treatment intervention: active CPAP
Control intervention: sham CPAP
Treatment duration: 3 months
Delivered by: voluntary use by participants
Outcomes Time for fatigue assessment: by the end of 3-month use of CPAP
Primary outcome: objective usage data of CPAP
Secondary outcome: FSS score
Notes Only people with sleep apnoea were recruited
This study was primarily aimed at testing the feasibility of CPAP to treat sleep apnoea
in people with stroke. Fatigue was measured as 1 of the symptoms of sleep apnoea for
the efficacy of CPAP
The investigators reported median scores and IQR of FSS and we requested mean scores
and SD from the investigators
Funding: National Institutes of Health Grant K23 NS051202 and National Center for
Research Resources Grant M01-RR000042
Risk of bias
Bias Authors’ judgement Support for judgement
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Brown 2013 (Continued)
Allocation concealment (selection bias) Low risk Quote: “The active and sham CPAP units
were identical in appearance, with the
exception of the barely discernible aug-
mented leak port on the latter, and made
similar sounds while on”; “blinding to sub-
ject conditionwas successfullymaintained”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Outcome assessors weremasked to
intervention allocation”
Intention-to-treat High risk Available-case analysis: only reported data
of participants who had completed the 3-
month follow-up
Choi-Kwon 2007
Methods Parallel randomised trial
Method of randomisation: computer-generated list of treatment numbers




Participants Location: South Korea
Setting: outpatient clinics
Number of participants: 83 at randomisation, 78 completed study, ITT analysis for 83
participants (80% male, mean age 56 years)
Treatment group: 40 (80% male, mean age 57 years, SD 8)
Control group: 43 (81% male, mean age 56 years, SD 8)
Stroke criteria: ischaemic or haemorrhagic stroke, criteria unclear
Time since stroke onset at randomisation: mean 14 months (range 3 to 28 months) after
stroke onset
Fatigue criteria: self reported experiences of PSF by participants
Other entry criteria: not SAH, not TIA, no psychiatric history
Comparability of groups: both mean scores of VAS-f and FSS were higher in placebo
group than in fluoxetine group at baseline. No significant difference at baseline regarding
demographics and stroke characteristics
Interventions Treatment intervention: fluoxetine 20 mg/day, single morning dose, orally
Control intervention: placebo 20 mg/day, single morning dose, orally
Treatment duration: 3 months
Delivered by: taken by participants at home
Outcomes Time for fatigue assessment: baseline, by the end of 3-month treatment, at 6-month
follow-up from baseline
Primary outcome: mean scores of FSS and VAS-f
Secondary outcome: percent changes in FSS andVAS scores between baseline and follow-
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Choi-Kwon 2007 (Continued)
up
Notes Only people reporting subjective experiences of PSF were recruited
Funding: a research fund from the Korean Ministry of Health and Welfare (03-PJI-
PGI-CH06-0001), and a grant from the Brain Research Center of the 21st Century
Frontier Research Program funded by the Ministry of Science and Technology of Korea
(M103KV010010 06K220101010)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Treatment allocation was based on a com-
puter-generated list of treatment numbers.
The control group used a placebo of iden-
tical appearance with fluoxetine
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were self reported by partici-
pants who were not aware of allocation
Intention-to-treat Low risk The primary efficacy analysis was done us-
ing ITT analysis. In addition, on-treatment
analysis was performed to see the consis-
tency of the primary results
5 participants (2 placebo, 3 treatment)
dropped out before completing the 3-
month treatment protocol, leaving 78 par-
ticipants. The reasons for the drop-outwere
protocol violation in 3 participants and ad-
verse effects in 2. The drop-out rate and
reasons for drop-out were not different be-
tween the 2 groups
Clarke 2012
Methods Parallel randomised trial
Method of randomisation: block randomisation
Method of concealment: unclear
Blinding: single-blind (participants)
Analysis: available-case analysis
Participants Location: New Zealand
Setting: stroke clinic or local community
Number of participants: 19 at randomisation, 16 completed study, case-available analysis
for 16 participants (62% male, mean age 72 years)
Treatment group: 9 (67% male, mean age 69 years)
Control group: 7 (57% male, mean age 76 years)
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Clarke 2012 (Continued)
Stroke criteria: ischaemic or haemorrhagic stroke, criteria unclear
Time since stroke onset at randomisation: 3 to 18 months after stroke (mean 8 months
for treatment group, 10 months for control group)
Fatigue criteria: FSS ≥ 4
Other entry criteria: medically stable and no significant impairments
Comparability of groups: the treatment group was younger and had stroke more recently
than control group. No significant difference of mean FSS scores between groups at base-
line. No significant difference at baseline in other demographics or stroke characteristics
Interventions Treatment intervention: 6 group psychoeducation sessions (targeting alleviating fatigue)
, 60 minutes weekly
Control intervention: 6 group psychoeducation sessions (general education without tar-
geting fatigue), 60 minutes weekly
Treatment duration: 6 weeks
Delivered by: a clinical psychologist
Outcomes Time for fatigue assessment: baseline, during the final treatment session, at 3-month
follow-up
Primary outcome: change on scores of FSS
Secondary outcome: VAS-f, CIS-f
Notes Only people with scores of FSS ≥ were recruited
Funding: no information available
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Quote: “This was a single-blind study, the
researcher knew which condition the pa-
tient had been allocated to, but the patients
were not aware. As the patient is not aware
of whether they are receiving the experi-
mental condition or the control condition,
there should be no placebo effect.However,
the researchers could unconsciously treat
the patients differently depending on the
condition and thus influence the outcome
of the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “This was a single-blind study, the
researcher know which condition the pa-
tient had been allocated to, but the pa-
tients were not aware.”; “Any possible ex-
perimenter effects were minimised by en-
suring all measures were self-report rather
than researcher rated”
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Clarke 2012 (Continued)
Intention-to-treat High risk Available-case analysis: 3 participants (2 in
treatment group and 1 in control group)
withdrew without attending any group ses-
sions. They were excluded from all further
analyses
Guo 2012
Methods Parallel randomised trial
Method of randomisation: random number table
Method of concealment: placebo-controlled, unclear whether the appearance was iden-
tical to the tested drug
Blinding: unclear
Analysis: no loss to follow-up
Participants Location: China
Setting: inpatients
Number of participants: 90 at randomisation and all completed the study (56% male,
mean age 66 years)
Treatment group 1: 30 (63% male, mean age 66 years)
Treatment group 2: 30 (50% male, mean age 66 years)
Control group: 30 (50% male, mean age 65 years)
Stroke criteria: ischaemic, criteria unclear
Time since stroke onset at randomisation: within 6 months after stroke onset (mean 1
month for each group)
Fatigue criteria: diagnosis of fatigue according to Traditional Chinese Medicine Diag-
nostic Criteria
Other entry criteria: 40 to 85 years, medically stable
Comparability of groups: no significant difference inmean scores of either FSS or SSQOL
between groups at baseline
Interventions Treatment 1 intervention: oral traditional Chinese medicine (Qi-supplementing domi-
nated decoction (Astragalus membranaceus 60 g, Ligusticum wallichii 15 g, Radix paeoniae
rubrathe 15 g, Andachyranthes bidentata 15 g), 100 mL, twice per day, 4 weeks) plus
intravenous traditional Chinese medicine (Radix ginseng rubra plus Radix ophiopogonis,
250 mL, daily, 14 days), and rehabilitation therapy (60 minutes, twice a day, 4 weeks)
Treatment 2 intervention: placebo oral traditional Chinese medicine (poria cocos 15 g,
rice sprout 20 g, malt 20 g and liquorice 10 g, 100 mL, twice per day, 4 weeks) plus
intravenous citicoline (500 mg/250 mL, daily, 14 days), and rehabilitation therapy (60
minutes, twice a day, 4 weeks)
Control intervention: placebo oral traditional Chinese medicine (100 mL, twice per day,
4 weeks) plus intravenous saline (250 mL, daily, 14 days), and rehabilitation therapy (60
minutes, twice a day, 4 weeks)
Treatment duration: 4 weeks
Delivered by: unclear
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Guo 2012 (Continued)
Outcomes Time for fatigue assessment: baseline and at the end of 4-week treatment
Primary outcome: mean FSS score after treatment
Secondary outcome: mean SSQOL score after treatment
Measured immediately at the end of 4-week treatment
Notes Only people with PSF were recruited
Funding: supported by the Natural Science Foundation of Guangdong Province, China
(Grant No. 2007B31400008)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Unclear whether the appearance of the
tested drug and placebo were identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by a rehabilitation
physician and a resident who were not in-
volved in the intervention
Intention-to-treat Low risk No loss to follow-up reported
Gurak 2005
Methods Parallel randomised trial
Method of randomisation: simple randomisation





Number of participants: 30 at randomisation and all completed the study (33% male,
mean age 51 years)
Treatment group: 15
Control group: 15
Stroke criteria: ischaemic, criteria unclear
Time since stroke onset at randomisation: > 3 months after stroke
Fatigue criteria: MFI-20
Other entry criteria: unclear
Comparability of groups: unclear
Interventions Treatment intervention: enerion (a synthetic derivative of vitamin B1, 200 mg, twice
per day, 30 days) plus standard rehabilitation
Control intervention: standard rehabilitation
Treatment duration: 30 days
Delivered by: unclear
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Gurak 2005 (Continued)
Outcomes Time for fatigue assessment: baseline and at the end of 30-day treatment
Primary outcome:MFI-20 (general fatigue, physical fatigue, low activity, lowmotivation
and mental fatigue)
Notes Only people with PSF (MFI-20) were recruited
Funding: no information available
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Interventions used in the 2 groups were vis-
ibly different, so participants and medical
staff would be aware of what was being used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information reported
Intention-to-treat Low risk No loss to follow-up reported
Johansson 2012a
Methods Cross-over design
Method of randomisation: “randomisation was done externally”
Method of concealment: “randomisation was done externally. Measures were taken to
guarantee blinding.” “Both the patients and all the study staff members were blinded.”





Number of participants: 6 at randomisation, 1 participant dropped out and 1 new
participant was recruited to take his place (67% male, mean age 50 years)
Treatment group: 4
Control group: 2
Stroke criteria: ischaemic and haemorrhagic, criteria unclear
Time since stroke onset at randomisation: 1 to 10 years (mean = 7 years)
Fatigue criteria: MFS ≥ 10
Other entry criteria: 1 to 10 years after stroke, 30 to 65 years old
Comparability of groups: unclear
Interventions Treatment intervention: oral monoaminergic stabiliser (-)-OSU6162 (week 1: 15 mg,
twice per day; week 2: 30 mg, twice per day; weeks 3 and 4: 45 mg, twice per day. The
dose was individually flexible for 4 weeks
Control intervention: oral placebo (week 1: 15 mg, twice per day; week 2: 30 mg, twice
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Johansson 2012a (Continued)
per day; weeks 3 and 4: 45 mg, twice per day. The dose was individually flexible for 4
weeks
Treatment duration: 4 weeks
Delivered by: unclear
Outcomes Time for fatigue assessment: baseline and at the end of 4-week treatment
Primary outcome: MFS
Notes Only people with PSF (MFS ≥ 10) were recruited
Only the results of the first cohort of this cross-over study were used in the current
systematic review
Funding: supported by the Arvid Carlsson Foundation and the Foundation for Neu-
ropharmacological Research and Education
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Quote: “Randomisation was done exter-
nally. Measures were taken to guarantee
blinding.” “Both the patients and all the
study staff members were blinded.” “The
code was broken only after all patients had
terminated the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Randomisation was done exter-
nally. Measures were taken to guarantee
blinding.” “Both the patients and all the
study staff members were blinded.” “The
code was broken only after all patients had
terminated the study”
Intention-to-treat High risk Quote: “In case of dropouts, new patients
were included in order to obtain six stroke
subjects”
Comments: the investigators only reported
the results of 6 people with stroke, which
consisted of 5 recruited at baseline and 1
recruited during the study, while data for
1 participant who dropped out were not
reported
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Johansson 2012b
Methods Cross-over design
Method of randomisation: randomised stated, method unclear
Method of concealment: wait-list controlled, thus no concealment
Blinding: wait-list controlled, thus no blinding
Analysis: no loss to follow-up
Participants Location: Sweden
Setting: community
Number of participants: mixed population of 29 participants with either stroke or trau-
matic brain injury at randomisation, 26 participants completed study of whom 16 were
people with stroke
Treatment group: 7 (age and sex unclear)
Control group: 9 (age and sex unclear)
Stroke criteria: ischaemic and haemorrhagic, criteria unclear
Time since stroke onset at randomisation: > 1 year after stroke
Fatigue criteria: MFS ≥ 10
Other entry criteria: > 1 year after stroke, 30 to 65 years old
Comparability of groups: the treatment group and the control group on did not differ
significantly in their self assessment of MFS at the start of the programme (P value = 0.
29)
Interventions Treatment intervention: mindfulness-based stress reduction (8 weekly group sessions, 2.
5 hours for each session, 1 silent led retreat between session 6 and session 7, and 45
minutes home practice for 6 days a week for 8 weeks
Control intervention: wait-list
Treatment duration: 8 weeks
Delivered by: unclear
Outcomes Time for fatigue assessment: baseline and by the end of 8-week treatment
Primary outcome: MFS
Notes Only people with PSF (MFS ≥ 10) were recruited
Only the results of the first cohort of this cross-over study were used in the current
systematic review
Funding: supported by grants from AFA Insurance and The Health & Medical Care
Committee of the Region Vastra Gotaland
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Wait-list controlled, so participants and
medical staff would be aware of what was
being used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information reported
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Johansson 2012b (Continued)
Intention-to-treat High risk Available-case analysis: only reported data
for participants who had completed the
study
Karaiskos 2012
Methods Parallel randomised trial
Method of randomisation: randomised stated, method unclear
Method of concealment: open-label
Blinding: open-label
Analysis: no loss to follow-up
Participants Location: Greece
Setting: outpatients
Number of participants: 60 participants at randomisation and all completed the study
(mean age 53 years, sex unclear)
Treatment group 1: 20 (mean age 51 years, sex unclear)
Treatment group 2: 20 (mean age 54 years, sex unclear)
Control group: 20 (mean age 52 years, sex unclear)
Stroke criteria: ischaemic and haemorrhagic, based on clinical history, physical exami-
nation and brain MRI
Time since stroke onset at randomisation: within 1 year after stroke
Fatigue criteria: participants did not have to have fatigue at recruitment
Other entry criteria: clinical diagnosis of depression, within 1 year after stroke
Comparability of groups: no significant differences between groups at baseline in demo-
graphics, stroke characteristics and fatigue scores
Interventions Treatment 1 intervention: oral duloxetine, 60 to 120 mg/day
Treatment 2 intervention: oral citalopram, 20 to 40 mg/day
Treatment 3 intervention: oral sertraline, 50 to 200 mg/day
Treatment duration: 3 months
Delivered by: unclear
Outcomes Time for fatigue assessment: baseline, 1 month, 2 months and 3 months after the start
of treatment
Primary outcome: Hamilton Rating Scale for Depression, Hamilton Rating Scale for
Anxiety
Secondary outcome: FSS
Notes Only people with post-stroke depression were recruited
Fatigue was measured as one of the symptoms of depression
Funding: no information available
Risk of bias
Bias Authors’ judgement Support for judgement
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Karaiskos 2012 (Continued)
Allocation concealment (selection bias) High risk “Open-label” trial, so participants and
medical staff would be aware of what was
being used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information reported
Intention-to-treat Low risk No loss to follow-up reported
Lorig 2001
Methods Parallel randomised trial
Method of randomisation: randomisation stated, methods unclear





Number of participants: 1140 participants who were over 40 years old and with heart
disease, lung disease, stroke or arthritis were randomised, of whom 125 were people with
stroke. 104 participants completed 6-month assessment
Treatment group: 58 (age and sex unclear)
Control group: 46 (age and sex unclear)
Stroke criteria: “completed cerebrovascular accident with neurologic handicap and nor-
mal mentation”
Time since stroke onset at randomisation: unclear
Fatigue criteria: participants did not have to have fatigue at recruitment
Other entry criteria: > 40 years old
Comparability of groups: unclear
Interventions Treatment intervention: 7 weekly group sessions each lasting 2.5 hours in community
centres where participants were taught CDSMP by peer leaders. This included teaching
about exercise programmes; the use of cognitive symptom management techniques;
nutritional change; fatigue and sleep management; use of community resources; use of
medications; dealing with emotions of fear, anger and depression; communication with
others; problem solving and decision making
Control intervention: a wait-list control, i.e. participants continued with usual care for
6 months and were then offered the CDSMP
Treatment duration: 7 weeks
Delivered by: 2 peer leaders who had received 20 hours of training taught the CDSMP,
using a detailed teaching manual
Outcomes Time for fatigue assessment: baseline and 6 months after randomisation
Primary outcome: ’health behaviours, health status, and health service utilisation’, where
the energy/fatigue scale from the Medical Outcomes Study was used to measure fatigue
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Lorig 2001 (Continued)
Notes This study was primarily aimed to improve health status, where fatigue was measured
by an energy subscale of a scale for health-related quality of life
Data for the 125 participants with stroke were provided by the investigators of the trial
Funding: the University of California Tobacco-related Disease Research Program (Grant
No. TR156) and AHCPR (Grant No. 5 RO1 HS06680)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk ’wait-list-controlled’, so participants and
medical staff would be aware of what was
being used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information reported
Intention-to-treat High risk Available-case analysis
Ogden 1998
Methods Parallel randomised trial
Method of randomisation: randomisation stated, methods unclear
Methodof concealment: double-blind, the codewas broken after the outcome assessment
Blinding: double-blind, the code was broken after the outcome assessment
Analysis: available-case analysis
Participants Location: New Zealand
Setting: inpatients
Number of participants: 31 women with SAH were randomised, 21 were eligible for 3-
month follow-up assessment of whom 18 completed this assessment (mean age 47 years)
Treatment group: 9 (mean age 45 years)
Control group: 9 (mean age 50 years)
Stroke criteria: SAH
Time since stroke onset at randomisation: at admission for SAH
Fatigue criteria: participants did not have to have fatigue at recruitment
Other entry criteria: unclear
Comparability of groups: unclear
Interventions Treatment intervention: tirilazad mesylate 100 mL (1.5 mg/mL) for 10 consecutive days
after onset of SAH, unknown delivery route
Control intervention: vehicle (sterile solution) 100 mL for 10 consecutive days after
onset of SAH, unknown delivery route
Treatment duration: 10 days
Delivered by: unclear
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Ogden 1998 (Continued)
Outcomes Time for fatigue assessment: 3 months after randomisation
Primary outcome: Glasgow Outcome Scale
Secondary outcome: self-reported experience of debilitating fatigue by participants
Notes People did not have to have fatigue to be recruited
Fatigue was assessed as one of the neuropsychological symptoms in a subgroup of 18
participants from the 31 participants recruited
Funding: the Health Research Council of New Zealand (Grant 95/291)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Quote: “double blind protocol.” “The drug
code was broken after all assessments had
been scored”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind protocol.” “The drug
code was broken after all assessments had
been scored”
Intention-to-treat High risk Available-case analysis
Zedlitz 2012
Methods Parallel randomised trial
Method of randomisation: block randomisation per treatment centre
Method of concealment: interventions used in the 2 groups were visibly different, so




Setting: community-dwelling, recruited from rehabilitation centres
Number of participants: 83 participants at randomisation, 73 completed treatment, 68
completed follow-up. ITT analysis for 83 participants (52% male, mean age 55 years)
Treatment 1 group: 38 (55% male, mean age 55 years)
Treatment 2 group: 45 (49% male, mean age 55 years)
Stroke criteria: ischaemic stroke, haemorrhagic stroke or SAH, criteria unclear
Time since stroke onset at randomisation: > 4 months after stroke, mean 3.9 years
Fatigue criteria: CIS-fatigue ≥ 40
Other entry criteria: more than 4 months after stroke, 18 to 70 years old, no cardiopul-
monary complications or psychiatric disorders
Comparability of groups: unclear
Interventions Treatment 1 intervention (CO): group cognitive therapy (emphasising pacing and re-
laxation), 2 hours each session, once a week, for 12 weeks
Treatment 2 intervention (COGRAT): CO plus physical training (walking on treadmill,
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Zedlitz 2012 (Continued)
strength training and homework assignment, 2 hours each session, twice a week, for 12
weeks)
Treatment duration: 12 weeks
Delivered by: CO was delivered by neuro-psychologists and GRAT was delivered by
physiotherapists
Outcomes Time for fatigue assessment: baseline, by the end of 12-week treatment, and at 3-month
follow-up
Primary outcome: CIS-f
Secondary outcomes: self observation list (for fatigue, pain and sleep), Hamilton Anxi-
ety and Depression Scale (for depression and anxiety), Stroke-adapted Sickness Impact
Profile-30, 6-minute walk test
Notes Only people with severe fatigue (CIS-f≥ 40) and > 4 months after stroke were recruited
Mainly focused on the change of scores before and after treatment within a group rather
than comparing between groups
Funding: a grant from the Dutch Health Research and Development (ZonMw) (Grant
No. 14350053)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Interventions used in the 2 groups were vis-
ibly different, so participants and medical
staff would be aware of what was being used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “assessor-blind”
Intention-to-treat Low risk Quote: “All further analyses were per-
formed on an intention-to-treat basis. Any
missing values after treatment were im-
puted by carrying the last observation for-
ward, adhering a conservative assumption
with respect to treatment effects”
Zhou 2010
Methods Parallel design
Method of randomisation: randomisation stated, methods unclear
Method of concealment: interventions used in the 2 groups were visibly different, so
participants and medical staff would be aware of what was being used
Blinding: unclear
Analysis: no loss to follow-up
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Zhou 2010 (Continued)
Participants Location: China
Setting: both inpatients and outpatients
Number of participants: 128 participants at randomisation and all completed the study
(59% male, mean age 57 years)
Treatment 1 group (electroacupuncture plus cupping): 64 (56% male, mean age 58
years)
Treatment 2 group (medication): 64 (62% male. mean age 56 years)
Stroke criteria: ischaemic stroke, criteria unclear
Time since stroke onset at randomisation: within 3 years after stroke, mean 6 months
Fatigue criteria: SSQOL-energy < 12
Other entry criteria: within 3 years after stroke, < 70 years old
Comparability of groups: unclear
Interventions Treatment 1 intervention (electroacupuncture plus cupping): electroacupuncture for 30
minutes daily, 10 days as 1 cycle, for 3 cycles with 2-day intervals between cycles, plus
cupping at back for 10 minutes, once every 2 days, for 5 weeks
Treatment 2 intervention (medication): oral sertraline (50 mg, daily, for 5 weeks), plus
oral compound aminobutyric acid and vitamin E capsules (2 capsules, 3 times per day,
for 5 weeks) and oral magnesium gluconate solution (1000 mg/10 mL, containing
magnesium 58.6 mg, 3 times per day, for 5 weeks)
Treatment duration: 5 weeks
Delivered by: rehabilitation therapists or physicians
Outcomes Time for fatigue assessment: baseline, at the end of 5-week treatment, at 2-month follow-
up
Primary outcome: SSQOL-energy at the end of treatment
Secondary outcome: SSQOL-energy at 2-month follow-up
Notes Only people with severe fatigue (SSQOL-energy subscale < 12) were recruited
Funding: no information available
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Interventions used in the 2 groups were vis-
ibly different, so participants and medical
staff would be aware of what was being used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information reported
Intention-to-treat Low risk No loss to follow-up reported
CDSMP: Chronic Disease Self-Management Programme
CIS-f: Checklist Individual Strength-fatigue subscale
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CPAP: continuous positive airway pressure
FSS: Fatigue Severity Scale
ITT: intention-to-treat
IQR: interquartile range
MFI-20: Multidimensional Fatigue Inventory-20
MFS: Mental Fatigue Scale
MRI: magnetic resonance imaging
PSF: post stroke fatigue
SAH: subarachnoid haemorrhage
SD: standard deviation
SF-36-vitality: Short Form-36 vitality subscale
SSQOL-energy: Stroke-specific Quality of Life-energy subscale
TIA: transient ischaemic attack
VAS-f: Visual Analogue Scale-fatigue
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allison 2007 Fatigue was not an outcome of the study
Brioschi 2009 Compared the effects of modafinil on subjective fatigue between participants with multiple sclerosis and partic-
ipants with stroke. No control group for people with stroke
Cruz 2013 Not specifically targeted fatigue: fatigue was assessed at the end of each hand-to-mouth task as a measure for the
tolerance of this intervention
Feys 2013 The study was a single-arm trial and did not specifically target fatigue
Kim 2012 Not a controlled trial: compared the results of participants from treatment group with those from a group of
non-synchronised, non-equivalent inpatients in the ward
Kirkevold 2012 The study was a single-arm trial that tested an intervention for post-stroke fatigue
Lin 2013 The study did not specifically target at fatigue: post-intervention exertional fatigue was assessed as a measure for
the tolerance of the intervention
Robinson 2003 Reported a mixed population of participants and the data for people with stroke could not be obtained
Sianni 2008 The study did not use randomised allocation
Underwood 2006 The study did not specifically target at fatigue: fatigue was assessed during the intervention as a measure for the
tolerance of the intervention
Wu 2014b The study is a single-arm trial that tested an intervention for post-stroke fatigue
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Characteristics of ongoing studies [ordered by study ID]
AFFINITY 2013
Trial name or title An Australian-led, investigator-initiated, multi-centre, prospective, randomised, parallel group, double-blind,
placebo-controlled trial to establish the effect(s) of routine administration of fluoxetine (20 mg once daily)
in patients with recent stroke
Methods RCT
Participants Target number of participants: 1600 people with stroke who are 2 to 15 days after stroke onset
Interventions Fluoxetine 20 mg, daily, or matching placebo capsule, for 6 months
Outcomes Primary outcome
Functional ability 180 days after randomisation measured by the modified Rankin Scale (mRS) using the
simplified modified Rankin Scale questionnaire (smRSq). Secondary outcomes at 180- and 365-day assess-
ments:
• improves participants’: survival, mood (Patient Health Questionnaire-9 item (PHQ-9)), cognitive
function (Telephone Interview of Cognitive Status (TICSm)), communication (Stroke Impact Scale (SIS));
motor function (SIS); overall health status (SIS); Health-Related Quality of Life (HRQoL) (EuroQoL (EQ-
5D-5L)) and functional ability (smRSq) at the 365 day assessment
• reduces: new diagnosis of depression requiring treatment with antidepressants; fatigue (vitality domain
of the Short Form 36 item, SF-36)
• has risks of serious adverse events that offset its benefits
• reduces the cost of health care over the first year and
• is cost-effective
Starting date 2013
Contact information Associate Professor Maree Hackett, The George Institute for Global Health, The University of Sydney. Tel.
+61 2 9993 4593 Email: mhackett@georgeinstitute.org.au
Professor Graeme Hankey, Royal Perth Hospital and The University of Western Australia
Notes The study is expected to end in 2018
Chuang 2013
Trial name or title A study of post-stroke pain and fatigue: clinical evaluation and treatment effect (NCT01913509)
Methods Randomised, parallel-controlled, single-blind (participants) trial
Participants Target number of participants: 160 participants who are > 6 months after a first-ever stroke, with self reported
hemiplegic shoulder pain and post-stroke fatigue in the past 7 days
Interventions For people with ambulatory ability:
Experimental intervention1: combined therapy of functional electrical stimulation (FES) and graded treadmill
training (GTT), 1 daily, 3 days per week, for 4 weeks
Control 1: conventional rehabilitation (CR) 1, 1 hour daily, 3 days per week, for 4 weeks
For people with non-ambulatory ability:
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Chuang 2013 (Continued)
Experimental intervention 2: combined therapy of FES and body weight supported treadmill training (BW-
STT), 1 hour daily, 3 days per week, for 4 weeks
Control 2: conventional rehabilitation 2, 1 hour daily, 3 days per week, for 4 weeks
Outcomes Numerical Rating Scale with Face Rating Scale (NRS-FRS) for pain and fatigue
Brief Pain Inventory and Brief Fatigue Inventory
Starting date August 2013
Contact information Li-Ling Chuang, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan
Tel. 886-3-2118800 ext 3177
Email: lchuang@mail.cgu.edu.tw
Notes This 3-year project will recruit 160 participants with chronic stroke and will be implemented in 4 stages:
• 1st stage: a test-retest study to investigate the reliability and validity of outcome measures of post-
stroke pain and fatigue in 80 participants
• 2nd stage: an RCT to investigate the effects of FES-GTT versus CR on pain and fatigue in 40
ambulatory participants
• 3rd stage: an RCT to investigate the effects of FES-BWSTT versus CR on pain and fatigue in 40
ambulatory participants
• 4th stage: a study to determine psychometric properties of the outcome measures
The study is expected to end in July 2016
EFFECTS 2014
Trial name or title Efficacy oF Fluoxetine - a randomisEd Controlled Trials in Stroke
Methods RCT
Participants Target number of participants: 1500 people with stroke who are 2 to 15 days after stroke onset
Interventions Fluoxetine 20 mg, daily, or matching placebo capsule, for 6 months
Outcomes The primary outcome measure is the proportion of independent survivors defined as modified Rankin Scale
(mRS) 0 to 2 at 6 months
Secondary outcomes
• Survival at 6 and 12 months
• Effect of daily life as measured by the Stroke Impact Scale
• Quality of life as measured by the scale EQ-5D-5L
• Influence of fatigue measured with the vitality subscale of 36-item Short Form
• The presence of the depression measured by Montgomery-Åsberg Depression Rating Scale (MADRS)
• Cognition, effects on memory and concentration measured by Montreal Cognitive Assessment
(MoCA)
• Neurological status including the presence of the effect on muscle strength or power of speech as
measured by the NIH Stroke Scale (NIHSS)
Starting date 2014
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EFFECTS 2014 (Continued)




Trial name or title Fluoxetine or control under supervision (FOCUS) trial (ISRCTN83290762)
Methods RCT
Participants Target number of participants: 3000 people with stroke who are 2 and 15 days after stroke onset
Interventions Fluoxetine 20 mg, daily, or matching placebo capsule, for 6 months
Outcomes Measured at 6 and 12 months after the start of treatment
Primary outcome: modified Rankin Scale at 6 months
Secondary outcomes:
• death from all causes at 6 and 12 months
• modified Rankin Scale at 12 months
• Stroke Impact Scale
• EuroQoL (EQ-5D-5L)
• Mental Health Inventory 5
• Vitality subscale of 36-item Short Form (as an assessment of fatigue)
• diagnosis of depression
• other adverse events
• adherence to the trial medication
• health and social care resources used during follow-up
Starting date July 2012
Contact information Gillian Mead, Department of Geriatric Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent,
EH16 4SA
Email: gillian.e.mead@ed.ac.uk
Notes Fatigue is one the secondary outcomes
The study is expected to end in October 2017
Liu 2012
Trial name or title Randomised, double blind, placebo control trial to evaluate the efficacy of Astragalus membranaceus in the
patients after stroke with fatigue (NCT01554787)
Methods Randomised, double-blind, placebo-controlled trial
Participants Target number of participants: 90 participants who are 3 months after stroke and with a fatigue score ≥ 4
(fatigue scale not specified), aged 40 to 80 years old
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Liu 2012 (Continued)
Interventions Astragalus membranaceus (Chinese herb) versus placebo
Outcomes Measured at 2-year follow-up
Primary outcomes: EORTC QLQ-C30 and BFI-T
Secondary outcome: 36-item Short Form
Starting date January 2012
Contact information Chung-Hsiang Liu, China Medical University Hospital, Taichung, Taiwan. Tel. 886-4-22052121 ext 7635
Email: greengen@gmail.com
Notes The estimated completion date of the study is December 2013. However, byNovember 2014, we identified no
relevant publication for this study. We contacted the investigator via email to request for further information
in November 2014 but received no reply prior to publication of this review
MacKay-Lyons 2012
Trial name or title Combined effects of aerobic exercise and cognitive training on cognition after stroke (NCT01674790)
Methods RCT
Participants Target number of participants: 20 participants who are > 6 months after stroke
Interventions Aerobic group: aerobic training (body weight support treadmill training at moderate to high intensity, i.e. 60
to 70% heart rate reserve, 20 minutes/day, 5 days/week, for 6 weeks) + motion exercise (non-aerobic passive
and active movement of upper and lower extremity, 20 minutes/day, 5 days/week, for 6 weeks)
Cognitive group: cognitive training (computerised dual N-back training programme, 20 minutes/day, 5
days/week, for 6 weeks) plus motion exercise (non-aerobic passive and active movement of upper and lower
extremity, 20 minutes/day, 5 days/week, for 6 weeks)
Aerobic plus cognitive group: aerobic training (body weight support treadmill training at moderate to high
intensity, i.e. 60 to 70% heart rate reserve, 20 minutes/day, 5 days/week, for 6 weeks) plus cognitive training
(computerised dual N-back training programme that involves a working memory task, 20 minutes/day, 5
days/week, for 6 weeks)
Control group: motion exercise (non-aerobic passive and active movement of upper and lower extremity, 20
minutes/day, 5 days/week, for 6 weeks) plus unstructured mental activity (e.g. listening to light novels on
tape, 20 minutes/day, 5 days/week, for 6 weeks)
Outcomes Measured at 10 weeks after the start of treatment
Primary outcomes: tests for cognition (Flanker test, Raven’s matrices test and Sternberg digit memory task)
Secondary outcomes
• peak oxygen consumption
• Fatigue Severity Scale-9
• Cognitive Failures Questionnaire
• Montreal Cognitive Assessment
• Expression of brain-derived neurotrophic factor and insulin-like growth factor-1 in peripheral blood
samples
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MacKay-Lyons 2012 (Continued)
Starting date September 2012
Contact information Marilyn MacKay-Lyons, Affiliated Scientist, Capital District Health Authority, Canada
Contact: Megan J Freeman
Email: mfreema7@gmail.com
Notes The study is expected to end in June 2015
Michael 2008
Trial name or title Testing adaptive physical activity in stroke (TAPAS) (NCT01042990)
Methods RCT
Participants Target number of participants: 54 participants who are > 6 months after an ischaemic stroke or who were >
1 year after a haemorrhagic stroke
Interventions Adaptive physical activity: a structured gait, balance and progressive walking programme in a group gym
setting, 3 times/week, for 6 months
Adaptive physical activity plus treadmill: a structured gait and balance programme in a group gym setting
plus progressive treadmill walking, 3 times/week, for 6 months
Control: education and instruction on a home exercise programme that participants do on their own
Outcomes Measured at 3 and 6 months after the start of treatment and at 3 months post-treatment
Primary outcomes (for physical fitness): VO2 peak, Berg Balance Scale, Dynamic Gait Index, Step Activity
Monitoring, 6-minute walks
Secondary outcomes: psychosocial questionnaires that includes fatigue as a self reported outcome measure
Starting date September 2008
Contact information Kathleen Michael, Baltimore VA Medical Center, University of Maryland, Baltimore, USA, 21201
Email: kmichael@grecc.umaryland.edu
Notes The estimated completion date of the study is September 2011.However, byNovember 2014, we identified no
relevant publication for this study. We contacted the investigator via email to request for further information
in November 2014 but received no reply prior to publication of this review
Overgaard 2012
Trial name or title Treatment of post stroke fatigue with a wakefulness promoting agent (NCT01800097)
Methods Randomised, placebo-controlled, double-blind trial for an intervention for post-stroke fatigue
Participants Target number of participants: 128 participants who have stroke within 14 days and had a score of Multidi-
mensional Fatigue Inventory-20 (MFI-20) of ≥ 12
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Overgaard 2012 (Continued)
Interventions Modafinil: tablet 400 mg (200 mg if ≥ 65 years), daily (morning dose), for 3 months
Placebo: tablet 400 mg (200 mg if ≥ 65 years), daily (morning dose), for 3 months
Outcomes Primary outcome: MFI-20 at 3 months
Secondary outcomes: MFI-20 at 1 and 6 months, Fatigue Severity Scale at 1, 3 and 6 months
Starting date October 2012
Contact information Karsten Overgaard, Herlev Hospital, Herlev, Denmark, 2730
Email: karsten.overgaard@regionh.dk
Notes The study is expected to end in August 2015
Vanroy 2010
Trial name or title The effect of an aerobic exercise programme in stroke patients (NCT01070459)
Methods Randomised, controlled, double-blind trial
Participants Target number of participants: 50 participants with first-ever stroke (ischaemic or haemorrhagic) and within
6 weeks after onset
Interventions Aerobic exercise group: aerobic training using a leg cycle bike, 30 minutes/session, 3 sessions/week, for 12
weeks; within the 12 weeks, 4 information sessions will be offered about risk factors of stroke, usefulness of
an active lifestyle and healthy eating. After the 12 weeks, half of the participants will be assigned to a group
that will get feedback on how to train their aerobic capacity within the following 9 months, while the other
half of the participants will not receive this feedback
Control group: passive mobilisation of the hemiplegic knee using a continuous passive motion device, 30
minutes/session, 3 sessions/week, for 12 weeks. After the 12 weeks, the participants will not receive any other
intervention
Outcomes Primary outcomes (for physical fitness): VO2 peak, strength, walking, activities of daily living (at baseline,
after 12 weeks’ training, 6 months, 1 year and 2 years after baseline)
Secondary outcomes
• post-stroke fatigue (by Checklist Individual Strength-20)
• depression
• lifestyle
• cardiovascular risk factors
Starting date February 2010
Contact information Christel Vanroy, Revalidatiewetenschappen en Kinesitherapie, Campus Drie Eiken - Lokaal S.022, Univer-
siteitsplein 1- 2610 Wilrijk, Belgium
Email: christel.vanroy@uantwerpen.be
Notes We contacted the investigator via email in November 2014. The investigator replied stating that “Study will
be finished in December 2014. I am currently working on those papers. Output will be expected in 2015 and
following”
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D A T A A N D A N A L Y S E S
Comparison 1. Trials primarily intended to treat fatigue (intervention versus control)




participants Statistical method Effect size
1 Continuous outcomes (subgroup
analysis)
6 244 Std. Mean Difference (IV, Random, 95% CI) -1.07 [-1.93, -0.21]
1.1 Pharmacological
interventions
4 209 Std. Mean Difference (IV, Random, 95% CI) -1.23 [-2.40, -0.06]
1.2 Non-pharmacological
interventions
2 35 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-1.37, 0.02]
2 Continuous outcomes
(sensitivity analysis)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Trials with adequate
allocation concealment
2 89 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-0.80, 0.04]
2.2 Trials with adequate
blinding of outcome assessors
4 198 Std. Mean Difference (IV, Random, 95% CI) -1.10 [-2.31, 0.11]
2.3 Trials using
intention-to-treat analysis
3 203 Std. Mean Difference (IV, Random, 95% CI) -1.41 [-2.73, -0.09]
2.4 Trials with no difference of
baseline fatigue scores between
groups
5 161 Std. Mean Difference (IV, Random, 95% CI) -1.22 [-2.34, -0.09]
2.5 Excluding the outlier 6 199 Std. Mean Difference (IV, Random, 95% CI) -0.49 [-0.78, -0.20]
3 Dichotomous outcomes 1 83 Risk Ratio (IV, Random, 95% CI) 0.89 [0.75, 1.05]
Comparison 3. Trials not primarily intended at post-stroke fatigue (individual results)




participants Statistical method Effect size
1 Brown 2011 (CPAP versus
sham, continuous outcome)
1 32 Mean Difference (IV, Random, 95% CI) 0.45 [-0.59, 1.49]
2 Lorig 2001 (CDSMP versus
wait-list, continuous outcome)
1 125 Mean Difference (IV, Random, 95% CI) -0.16 [-0.44, 0.12]
3 Ogden 1998 (tirilazad versus
vehicle, dichotomous outcome)
1 31 Risk Ratio (IV, Random, 95% CI) 0.42 [0.16, 1.07]
4 Karaiskos 2012 (duloxetine
versus citalopram, continuous
outcome
1 40 Mean Difference (IV, Random, 95% CI) -0.20 [-0.95, 0.55]
5 Karaiskos 2012 (duloxetine
versus sertraline, continuous
outcome
1 40 Mean Difference (IV, Random, 95% CI) -0.30 [-1.08, 0.48]
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6 Karaiskos 2012 (citalopram
versus sertraline, continuous
outcome)
1 40 Mean Difference (IV, Random, 95% CI) -0.10 [-0.94, 0.74]
Analysis 1.1. Comparison 1 Trials primarily intended to treat fatigue (intervention versus control),
Outcome 1 Continuous outcomes (subgroup analysis).
Review: Interventions for post-stroke fatigue
Comparison: 1 Trials primarily intended to treat fatigue (intervention versus control)
Outcome: 1 Continuous outcomes (subgroup analysis)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Pharmacological interventions
Guo 2012 30 2.09 (0.47) 15 5.33 (1.09) 13.4 % -4.35 [ -5.48, -3.22 ]
Gurak 2005 15 13 (2.5) 15 15.6 (2.2) 15.3 % -1.07 [ -1.85, -0.30 ]
Choi-Kwon 2007 40 3.7 (1.6) 43 4.3 (1.5) 16.7 % -0.38 [ -0.82, 0.05 ]
Johansson 2012a 4 13.13 (5.59) 2 15.5 (9.9) 10.3 % -0.27 [ -1.99, 1.44 ]
Guo 2012 30 5.07 (1.3) 15 5.33 (1.09) 16.0 % -0.21 [ -0.83, 0.41 ]
Subtotal (95% CI) 119 90 71.7 % -1.23 [ -2.40, -0.06 ]
Heterogeneity: Tau2 = 1.53; Chi2 = 45.84, df = 4 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.06 (P = 0.039)
2 Non-pharmacological interventions
Johansson 2012b 7 16 (5.42) 9 21.56 (5.04) 13.8 % -1.01 [ -2.08, 0.06 ]
Clarke 2012 11 4.51 (1.27) 8 4.97 (0.54) 14.5 % -0.43 [ -1.35, 0.50 ]
Subtotal (95% CI) 18 17 28.3 % -0.68 [ -1.37, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
Total (95% CI) 137 107 100.0 % -1.07 [ -1.93, -0.21 ]
Heterogeneity: Tau2 = 1.10; Chi2 = 46.52, df = 6 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
-10 -5 0 5 10
Favours Interventions Favours Control
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Analysis 1.2. Comparison 1 Trials primarily intended to treat fatigue (intervention versus control),
Outcome 2 Continuous outcomes (sensitivity analysis).
Review: Interventions for post-stroke fatigue
Comparison: 1 Trials primarily intended to treat fatigue (intervention versus control)
Outcome: 2 Continuous outcomes (sensitivity analysis)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Trials with adequate allocation concealment
Choi-Kwon 2007 40 3.7 (1.6) 43 4.3 (1.5) 94.0 % -0.38 [ -0.82, 0.05 ]
Johansson 2012a 4 13.13 (5.59) 2 15.5 (9.9) 6.0 % -0.27 [ -1.99, 1.44 ]
Subtotal (95% CI) 44 45 100.0 % -0.38 [ -0.80, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.079)
2 Trials with adequate blinding of outcome assessors
Guo 2012 30 2.09 (0.47) 15 5.33 (1.09) 19.3 % -4.35 [ -5.48, -3.22 ]
Clarke 2012 11 4.51 (1.27) 8 4.97 (0.54) 20.4 % -0.43 [ -1.35, 0.50 ]
Choi-Kwon 2007 40 3.7 (1.6) 43 4.3 (1.5) 22.5 % -0.38 [ -0.82, 0.05 ]
Johansson 2012a 4 13.13 (5.59) 2 15.5 (9.9) 15.8 % -0.27 [ -1.99, 1.44 ]
Guo 2012 30 5.07 (1.3) 15 5.33 (1.09) 21.9 % -0.21 [ -0.83, 0.41 ]
Subtotal (95% CI) 115 83 100.0 % -1.10 [ -2.31, 0.11 ]
Heterogeneity: Tau2 = 1.63; Chi2 = 45.23, df = 4 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.79 (P = 0.074)
3 Trials using intention-to-treat analysis
Guo 2012 30 2.09 (0.47) 15 5.33 (1.09) 22.8 % -4.35 [ -5.48, -3.22 ]
Gurak 2005 15 13 (2.5) 15 15.6 (2.2) 25.0 % -1.07 [ -1.85, -0.30 ]
Choi-Kwon 2007 40 3.7 (1.6) 43 4.3 (1.5) 26.5 % -0.38 [ -0.82, 0.05 ]
Guo 2012 30 5.07 (1.3) 15 5.33 (1.09) 25.7 % -0.21 [ -0.83, 0.41 ]
Subtotal (95% CI) 115 88 100.0 % -1.41 [ -2.73, -0.09 ]
Heterogeneity: Tau2 = 1.66; Chi2 = 45.55, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.10 (P = 0.036)
4 Trials with no difference of baseline fatigue scores between groups
Guo 2012 30 2.09 (0.47) 15 5.33 (1.09) 16.3 % -4.35 [ -5.48, -3.22 ]
Gurak 2005 15 13 (2.5) 15 15.6 (2.2) 17.9 % -1.07 [ -1.85, -0.30 ]
Johansson 2012b 7 16 (5.42) 9 21.56 (5.04) 16.6 % -1.01 [ -2.08, 0.06 ]
Clarke 2012 11 4.51 (1.27) 8 4.97 (0.54) 17.3 % -0.43 [ -1.35, 0.50 ]
-10 -5 0 5 10
Favours Interventions Favours Control
(Continued . . . )
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(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Johansson 2012a 4 13.13 (5.59) 2 15.5 (9.9) 13.4 % -0.27 [ -1.99, 1.44 ]
Guo 2012 30 5.07 (1.3) 15 5.33 (1.09) 18.4 % -0.21 [ -0.83, 0.41 ]
Subtotal (95% CI) 97 64 100.0 % -1.22 [ -2.34, -0.09 ]
Heterogeneity: Tau2 = 1.69; Chi2 = 42.40, df = 5 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.12 (P = 0.034)
5 Excluding the outlier
Gurak 2005 15 13 (2.5) 15 15.6 (2.2) 14.0 % -1.07 [ -1.85, -0.30 ]
Johansson 2012b 7 16 (5.42) 9 21.56 (5.04) 7.4 % -1.01 [ -2.08, 0.06 ]
Clarke 2012 11 4.51 (1.27) 8 4.97 (0.54) 9.8 % -0.43 [ -1.35, 0.50 ]
Choi-Kwon 2007 40 3.7 (1.6) 43 4.3 (1.5) 44.3 % -0.38 [ -0.82, 0.05 ]
Johansson 2012a 4 13.13 (5.59) 2 15.5 (9.9) 2.8 % -0.27 [ -1.99, 1.44 ]
Guo 2012 30 5.07 (1.3) 15 5.33 (1.09) 21.7 % -0.21 [ -0.83, 0.41 ]
Subtotal (95% CI) 107 92 100.0 % -0.49 [ -0.78, -0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.22, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.31 (P = 0.00092)
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Analysis 1.3. Comparison 1 Trials primarily intended to treat fatigue (intervention versus control),
Outcome 3 Dichotomous outcomes.
Review: Interventions for post-stroke fatigue
Comparison: 1 Trials primarily intended to treat fatigue (intervention versus control)
Outcome: 3 Dichotomous outcomes
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Choi-Kwon 2007 33/40 40/43 100.0 % 0.89 [ 0.75, 1.05 ]
Total (95% CI) 40 43 100.0 % 0.89 [ 0.75, 1.05 ]
Total events: 33 (Experimental), 40 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Fluoxetine Favours Placebo
Analysis 3.1. Comparison 3 Trials not primarily intended at post-stroke fatigue (individual results),
Outcome 1 Brown 2011 (CPAP versus sham, continuous outcome).
Review: Interventions for post-stroke fatigue
Comparison: 3 Trials not primarily intended at post-stroke fatigue (individual results)
Outcome: 1 Brown 2011 (CPAP versus sham, continuous outcome)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2013 15 3.11 (1.3) 17 2.66 (1.69) 100.0 % 0.45 [ -0.59, 1.49 ]
Total (95% CI) 15 17 100.0 % 0.45 [ -0.59, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours active CPAP Favours sham CPAP
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Analysis 3.2. Comparison 3 Trials not primarily intended at post-stroke fatigue (individual results),
Outcome 2 Lorig 2001 (CDSMP versus wait-list, continuous outcome).
Review: Interventions for post-stroke fatigue
Comparison: 3 Trials not primarily intended at post-stroke fatigue (individual results)
Outcome: 2 Lorig 2001 (CDSMP versus wait-list, continuous outcome)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lorig 2001 67 0.087 (0.988) 58 0.25 (0.6) 100.0 % -0.16 [ -0.44, 0.12 ]
Total (95% CI) 67 58 100.0 % -0.16 [ -0.44, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours CDSMP Favours wait-list
Analysis 3.3. Comparison 3 Trials not primarily intended at post-stroke fatigue (individual results),
Outcome 3 Ogden 1998 (tirilazad versus vehicle, dichotomous outcome).
Review: Interventions for post-stroke fatigue
Comparison: 3 Trials not primarily intended at post-stroke fatigue (individual results)
Outcome: 3 Ogden 1998 (tirilazad versus vehicle, dichotomous outcome)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ogden 1998 4/16 9/15 100.0 % 0.42 [ 0.16, 1.07 ]
Total (95% CI) 16 15 100.0 % 0.42 [ 0.16, 1.07 ]
Total events: 4 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tirilazad Favours vehicle
54Interventions for post-stroke fatigue (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 Trials not primarily intended at post-stroke fatigue (individual results),
Outcome 4 Karaiskos 2012 (duloxetine versus citalopram, continuous outcome.
Review: Interventions for post-stroke fatigue
Comparison: 3 Trials not primarily intended at post-stroke fatigue (individual results)
Outcome: 4 Karaiskos 2012 (duloxetine versus citalopram, continuous outcome





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Karaiskos 2012 20 3.7 (1.1) 20 3.9 (1.3) 100.0 % -0.20 [ -0.95, 0.55 ]
Total (95% CI) 20 20 100.0 % -0.20 [ -0.95, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours duloxetine Favours citalopram
Analysis 3.5. Comparison 3 Trials not primarily intended at post-stroke fatigue (individual results),
Outcome 5 Karaiskos 2012 (duloxetine versus sertraline, continuous outcome.
Review: Interventions for post-stroke fatigue
Comparison: 3 Trials not primarily intended at post-stroke fatigue (individual results)
Outcome: 5 Karaiskos 2012 (duloxetine versus sertraline, continuous outcome





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Karaiskos 2012 20 3.7 (1.1) 20 4 (1.4) 100.0 % -0.30 [ -1.08, 0.48 ]
Total (95% CI) 20 20 100.0 % -0.30 [ -1.08, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours duloxetine Favours sertraline
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Analysis 3.6. Comparison 3 Trials not primarily intended at post-stroke fatigue (individual results),
Outcome 6 Karaiskos 2012 (citalopram versus sertraline, continuous outcome).
Review: Interventions for post-stroke fatigue
Comparison: 3 Trials not primarily intended at post-stroke fatigue (individual results)
Outcome: 6 Karaiskos 2012 (citalopram versus sertraline, continuous outcome)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Karaiskos 2012 20 3.9 (1.3) 20 4 (1.4) 100.0 % -0.10 [ -0.94, 0.74 ]
Total (95% CI) 20 20 100.0 % -0.10 [ -0.94, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.81)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours citalopram Favours sertraline
A D D I T I O N A L T A B L E S
Table 1. Participant characteristics and study design of eight trials primarily intended to treat post-stroke fatigue
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Wait-list 8 weeks (for
the first
phase)
MFS MFS scores* Not applica-
ble
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Table 1. Participant characteristics and study design of eight trials primarily intended to treat post-stroke fatigue (Continued)
tion of treat-
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CIS-f: Checklist Individual Strength-fatigue subscale
FSS: Fatigue Severity Scale
MFI-20: Multidimensional Fatigue Inventory-20
MFS: Mental Fatigue Scale
n: number of participants
PSF: post-stroke fatigue
RCT: randomised controlled trial
SOL-f: Self-Observation List-fatigue subscale
SSQOL-energy: Energy subscale of Stroke-specific Quality of Life
TCM: traditional Chinese medicine
1. For outcomes of fatigue by the end of treatment, review authors calculated the effect size for each outcome according to the type
of outcomes, that is, standardised mean difference (SMD) or mean difference (MD) for continuous outcomes and risk ratio (RR) for
dichotomous outcomes: *Outcomes from 6 trials were included in meta-analysis, while the other 2 trials that did not have a control
arm were not included in meta-analysis; **Zhou 2010 presented SSQOL-energy scores graphically without reporting exact values, thus
the review authors were unable to calculate the effect size for this outcome.
2. These two trials enrolled mixed population of participants with stroke or brain injury, and used a cross-over study design. Trial
investigators provided unpublished data of results of the first phase (i.e. before the participants were crossed over to the other group)
for the subgroup of people with stroke.
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CDSMP: Chronic Disease Self-management Programme
CI: confidence interval
CPAP: continuous positive airway pressure
GOS: Glasgow Outcome Scale
MD: mean difference
n: number of participants
RR: risk ratio
SD: standard deviation
1 We calculated the effect size using the intention-to-treat analysis, that is, based on the number of participants and their grouping at
recruitment.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1. [mh ˆ“cerebrovascular disorders”] or [mh “basal ganglia cerebrovascular disease”] or [mh “brain ischemia”] or [mh “carotid artery
diseases”] or [mh “cerebrovascular trauma”] or [mh “intracranial arterial diseases”] or [mh “ intracranial arteriovenous
malformations”] or [mh “intracranial embolism and thrombosis”] or [mh “intracranial hemorrhages”] or [mh ˆstroke] or [mh “brain
infarction”] or [mh ˆ“vertebral artery dissection”]
2. (stroke or poststroke or “post-stroke” or cerebrovasc* or brain next vasc* or cerebral next vasc* or cva* or apoplex* or SAH):ti,ab
3. ((brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch*emi* or infarct* or thrombo* or emboli* or occlus*)):
ti,ab
4. ((brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*)):ti,ab
5. [mh ˆhemiplegia] or [mh paresis] or [mh “Gait Disorders, Neurologic”]
6. (hemipleg* or hemipar* or paresis or paretic):ti,ab
7. #1 or #2 or #3 or #4 or #5 or #6
8. [mh ˆfatigue] or [mh ˆ“fatigue syndrome, chronic”] or [mh âsthenia] or [mh ˆ“mental fatigue”] or [mh ˆ“muscle fatigue”] or
[mh ˆlethargy]
9. (fatigue* or astheni* or neurastheni* or tired or tiredness or weary or weariness or exhausted or exhaustion or lassitude or
listlessness or letharg* or apath* or malaise):ti,ab
10. ((low or lack) near/5 energy):ti,ab
11. #8 or #9 or #10
12. #7 and #11
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Appendix 2. MEDLINE search strategy
The trial search co-ordinator (BT) of the Cochrane Stroke Group developed the search strategies for the 2008 review and amended
them for the 2014 review. The following search strategy was used for MEDLINE and adapted for other databases in the 2014 review.
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or
exp cerebrovascular trauma/ or exp intracranial arterial diseases/ or exp intracranial arteriovenous malformations/ or exp “intracranial
embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or
occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or
haematoma$ or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/ or exp Gait Disorders, Neurologic/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. fatigue/ or fatigue syndrome, chronic/ or asthenia/ or mental fatigue/ or muscle fatigue/ or lethargy/
9. (fatigue$ or astheni$ or neurastheni$ or tired or tiredness or weary or weariness or exhausted or exhaustion or lassitude or
listlessness or letharg$ or apath$ or malaise).tw.
10. ((low or lack) adj5 energy).tw.
11. 8 or 9 or 10
12. 7 and 11
13. exp animals/ not humans.sh.
14. 12 not 13
15. Randomized Controlled Trials as Topic/
16. random allocation/
17. Controlled Clinical Trials as Topic/
18. control groups/
19. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or







26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
29. (random$ or RCT or RCTs).tw.
30. (controlled adj5 (trial$ or stud$)).tw.
31. (clinical$ adj5 trial$).tw.
32. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
33. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
34. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
35. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
36. (cross-over or cross over or crossover).tw.
37. (placebo$ or sham).tw.
38. trial.ti.
39. (assign$ or allocat$).tw.
40. controls.tw.
41. or/15-40
42. 14 and 41
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Appendix 3. EMBASE search strategy
1. stroke/ or cerebrovascular disease/ or exp basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp
brain infarction/ or exp brain ischemia/ or carotid artery disease/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp
cerebrovascular malformation/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular disease/
2. stroke unit/ or stroke patient/
3. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or
occlus$)).tw.
5. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or
haematoma$ or hematoma$ or bleed$)).tw.
6. hemiplegia/ or paresis/ or exp neurologic gait disorder/
7. (hemipleg$ or hemipar$ or paresis or paretic).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. fatigue/ or chronic fatigue syndrome/ or exhaustion/ or lassitude/ or muscle fatigue/ or Fatigue Impact Scale/ or Fatigue Severity
Scale/
10. lethargy/ or listlessness/ or malaise/ or apathy/ or dysthymia/ or asthenia/ or neurasthenia/
11. (fatigue$ or astheni$ or neurastheni$ or tired or tiredness or weary or weariness or exhausted or exhaustion or lassitude or
listlessness or letharg$ or apath$ or malaise).tw.
12. ((low or lack) adj5 energy).tw.
13. 9 or 10 or 11 or 12
14. 8 and 13
15. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not
(human/ or normal human/ or human cell/)
16. 14 not 15




21. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled
clinical trial/
22. Crossover Procedure/
23. Double Blind Procedure/
24. Single Blind Procedure/ or triple blind procedure/
25. placebo/
26. (random$ or RCT or RCTs).tw.
27. (controlled adj5 (trial$ or stud$)).tw.
28. (clinical$ adj5 trial$).tw.
29. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
30. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
31. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
32. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
33. (cross-over or cross over or crossover).tw.
34. (placebo$ or sham).tw.
35. trial.ti.
36. (assign$ or allocat$).tw.
37. controls.tw.
38. or/17-37
39. 16 and 38
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Appendix 4. CINAHL search strategy
• S1 .(MH “Cerebrovascular Disorders”) OR (MH “Basal Ganglia Cerebrovascular Disease+”) OR (MH “Carotid Artery
Diseases+”) OR (MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR (MH “Intracranial Arterial Diseases+”) OR (MH
“Intracranial Embolism and Thrombosis”) OR (MH “Intracranial Hemorrhage+”) OR (MH “Stroke”) OR (MH “Vertebral Artery
Dissections”)
• S2 .(MH “Stroke Patients”) OR (MH “Stroke Units”)
• S3 .TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH ) or AB (
stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH )
• S4 .TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or
intracerebral )
• S5 .TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or ischaemi* or infarct* or
thrombo* or emboli* or occlus* )
• S6 .S4 and S5
• S7 .TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid ) or AB ( brain* or cerebr* or cerebell* or
intracerebral or intracranial or subarachnoid )
• S8 .TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed* )
• S9 .S7 and S8
• S10 .(MH “Hemiplegia”)
• S11 .TI ( hemipleg* or hemipar* or paresis or paretic ) or AB ( hemipleg* or hemipar* or paresis or paretic )
• S12 .S1 or S2 or S3 or S6 or S9 or S10 or S11
• S13 .(MH “Fatigue”) OR (MH “Fatigue Syndrome, Chronic”) OR (MH “Asthenia”)
• S14 .(MH “Fatigue (NANDA)”) OR (MH “Fatigue (Saba CCC)”)
• S15 .(MH “Muscle Fatigue”)
• S16 .TI ( fatigue* or astheni* or neurastheni* or tired or tiredness or weary or weariness or exhausted or exhaustion or lassitude
or listlessness or letharg* or apath* or malaise ) or AB ( fatigue* or astheni* or neurastheni* or tired or tiredness or weary or weariness
or exhausted or exhaustion or lassitude or listlessness or letharg* or apath* or malaise )
• S17 .TI ( (low N5 energy) or (lack* N5 energy) ) or AB ( (low N5 energy) or (lack* N5 energy) )
• S18 .S13 or S14 or S15 or S16 or S17
• S19 .S12 and S18
Appendix 5. AMED search strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or cerebral infarction/ or cerebral ischemia/ or cerebrovascular accident/ or
stroke/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or
occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or
haematoma$ or hematoma$ or bleed$)).tw.
5. hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. fatigue/ or fatigue mental/ or fatigue syndrome chronic/ or muscle fatigue/
9. (fatigue$ or astheni$ or neurastheni$ or tired or tiredness or weary or weariness or exhausted or exhaustion or lassitude or
listlessness or letharg$ or apath$ or malaise).tw.
10. ((low or lack) adj5 energy).tw.
11. 8 or 9 or 10
12. 7 and 11
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Appendix 6. PsycInfo search strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebrovascular accidents/ or subarachnoid
hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or
occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or
haematoma$ or hematoma$ or bleed$)).tw.
5. hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. fatigue/ or chronic fatigue syndrome/ or hypersomnia/ or sleepiness/ or asthenia/ or neurasthenia/ or apathy/ or dysthymic
disorder/
9. (fatigue$ or astheni$ or neurastheni$ or tired or tiredness or weary or weariness or exhausted or exhaustion or lassitude or
listlessness or letharg$ or apath$ or malaise).tw.
10. ((low or lack) adj5 energy).tw.
11. 8 or 9 or 10
12. 7 and 11
Appendix 7. ProQuest search strategy
all(stroke OR poststroke OR post-stroke OR cerebrovasc* OR brain vasc* OR cerebral vasc* OR cva* OR apoplexy* OR subarachnoid
OR hemipleg* OR hemipar* OR paresis OR paretic) AND all(fatigue OR hypersomnia OR sleepiness OR asthenia OR neurasthenia
OR apathy OR dysthymic disorder OR tired OR tiredness OR weary OR weariness OR exhausted OR exhaustion OR lassitude OR
listlessness OR lethargy* OR apathy* OR malaise OR low NEAR/3 energy OR lack* NEAR/3 energy)
Appendix 8. British Nursing Index search strategy
1. (“cerebrovascular disorder” OR “cerebrovascular disorders” OR (“cerebral hemorrhage” or “cerebral haemorrhage”) OR
(“cerebral ischemia” or “cerebral ischaemia”) OR (“cerebrovascular accident” or “CVA”) OR ((“subarachnoid hemorrhage” or
“subarachnoid haemorrhage”) OR (“subarachnoid hemorrhages” or “subarachnoid haemorrhages”))) OR (cerebrovascular disorder
OR cerebral hemorrhage OR cerebral haemorrhage OR cerebral ischemia OR cerebral ischaemia OR cerebrovascular accident OR
subarachnoid hemorrhage)
2. (SU.EXACT.EXPLODE(“Stroke”) OR “Stroke” OR Stroke) OR (poststroke OR “poststroke” OR “post-stroke” OR post-
stroke) OR cerebrovasc* OR (brain vasc*) OR (cerebral vasc*) OR cerebrovasc* OR cerebro-vasc* OR (CVA or “CVA”) OR apoplex*
OR (SAH or “SAH”)
3. (brain* or cerebr* or cerebell* or intracran* or intracerebral) NEAR/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus*)
4. (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) NEAR/5 (haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*)
5. hemiplegia OR “hemiplegia”
6. hemipleg* OR hemipar* OR paresis OR paretic
7. 1 or 2 or 3 or 4 or 5 or 6
8. “hypersomnia” OR “sleepiness” OR “asthenia” OR “neurasthenia” OR “apathy” OR “dysthymic disorder” OR
(SU.EXACT.EXPLODE(“Chronic Fatigue Syndrome”) OR SU.EXACT.EXPLODE(“Fatigue”))
9. fatigue* or astheni* or neurastheni* or tired or tiredness or weary or weariness or exhausted or exhaustion or lassitude or
listlessness or letharg* or apath* or malaise
10. (low or lack) NEAR/5 energy
11. 8 or 9 or 10
12. 7 and 11
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WH A T ’ S N E W
Last assessed as up-to-date: 13 May 2014.
Date Event Description
1 March 2015 New citation required and conclusions have changed This current version of the review found a marginally sta-
tistically significant effect of pharmacological interventions
(but not non-pharmacological interventions) on fatigue af-
ter stroke. However, there is no robust evidence to guide
the prevention or treatment of fatigue after stroke, because
the existing trials were small and heterogeneous, and some
had a high risk of bias. The delivery of some non-pharma-
cological interventions was feasible in stroke patients, but
efficacy should be investigated in further trials with more
robust study design
1 March 2015 New search has been performed We have added nine newpublished trials (of which twowere
ongoing trials in the previous review). We identified nine
ongoing trials (compared with two in the previous review)
We included 12 published trials in total with a total of
703 participants (compared with three trials in the previous
version). Of these 12 trials, six trials provided data suitable
for pooling and six did not
H I S T O R Y
Protocol first published: Issue 2, 2008
Review first published: Issue 3, 2009
Date Event Description
1 March 2015 New search has been performed There has been a change of authorship.
C O N T R I B U T I O N S O F A U T H O R S
For the 2008 review, Gillian Mead, Martin Dennis, Michael Sharpe and Susan Lewis wrote the protocol. Elizabeth Keane, Gillian
Mead, Alex Pollock and Lorraine Smith performed the searches, selected studies fulfilling the inclusion criteria and extracted data.
Susan Lewis provided advice on statistical analysis and interpretation. Elizabeth Keane and Gillian Mead drafted the review. All authors
edited the review and all approved the final version.
For this updated review, Alex Pollock, Malcolm Macleod, Martin Dennis and Gillian Mead provided advice on review methods and
Simiao Wu clarified aspects of the protocol. Simiao Wu, Eileen Cowey and Mansur Kutlubaev performed the searches. Simiao Wu,
Ho-Yan Yvonne Chun, Eileen Cowey, Mansur Kutlubaev and Gillian Mead selected studies. Simiao Wu, Ho-Yan Yvonne Chun and
Mansur Kutlubaev extracted data. Simiao Wu analysed data. Simiao Wu and Gillian Mead drafted the review. Alex Pollock, Eileen
Cowey, Malcolm Macleod, Michael Sharpe and Mansur Kutlubaev edited the review. All authors approved the final version.
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D E C L A R A T I O N S O F I N T E R E S T
Simiao Wu: none known.
Mansur A Kutlubaev: none known.
Ho-Yan Y Chun: none known.
Eileen Cowey: none known.
Alex Pollock: none known.
Malcolm Macleod: is an employee of the University of Edinburgh and the Medicines & Healthcare products Regulatory Agency
(MHRA), and receives honoraria relating to book and journal publishing.
Martin Dennis: none known.
Elizabeth Keane: none known.
Michael Sharpe: for the 2008 review, Michael Sharpe received a research grant from the Scottish Government Chief Scientist Office to
carry out research on a related topic. He is currently employed by the University of Oxford. He has no competing interests.
Gillian Mead: has been awarded a project grant from the Scottish Government Chief Scientist Office to perform a longitudinal study
of fatigue after stroke. The preliminary results of this Cochrane review were used in the application for funding to justify the need
for further studies in this area. She has developed a course on exercise after stroke, which was licensed to Later Life Training who pay
royalties for the course. She has received expenses for speaking at conferences on exercise and fatigue after stroke.
S O U R C E S O F S U P P O R T
Internal sources
• University of Edinburgh, UK.
(Simiao Wu, Ho-Yan Yvonne, Gillian Mead, Malcolm Macleod, Martin Dennis)
• Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, UK.
(Alex Pollock)
• Nursing and Health Care School, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.
(Eileen Cowey)
• University of Oxford, UK.
(Michael Sharpe)
• NHS Lothian, UK.
(Gillian Mead, Susan Lewis, Martin Dennis, Elizabeth Keane)
• Chief Scientist Office, Scottish Government, UK.
(Alex Pollock)
External sources
• Scottish Branch of the British Geriatrics Society, UK.
Small project grant to Elizabeth Keane for searches and retrieval of articles for the 2008 review
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Clarification of types of studies and types of participants included in this review
In the 2008 review, we stated that we would include trials “where the interventions were aimed at treating fatigue”. However, we
included some trials that were not primarily intended to treat fatigue but reported fatigue as an outcome (e.g. Lorig 2001). Thus, in
the current review, we clarified this inclusion criterion by listing all eligible types of studies: 1. trials primarily intended to treat fatigue,
2. trials primarily intended to prevent fatigue and 3. trials not primarily intended to treat or prevent fatigue but which reported fatigue
as an outcome.
In the 2008 review, we stated that we would include “relevant randomised controlled trials in patients with a clinical diagnosis of
stroke”, but we included some trials that had recruited mix populations of participants with difference diseases including stroke (e.g.
Lorig 2001), where we were able to obtain data on just the participants with stroke. Thus, in the current review, we clarified that we
also included studies “which reported mixed populations of participants if more than 75% of the people were stroke or separate data
for people with stroke were obtained”.
Measures of treatment effects
In the 2008 review, we stated that if a study used a number of different measures for fatigue, we preferred the dichotomous measures as
primary outcomes to the continuous measures. In the current review, we performed different analyses for dichotomous outcomes and
for continuous outcomes.
Assessment of publication bias
We added methods for assessing the publication bias.
Synthetic analysis and effect size
We had planned to calculate standardised mean difference (SMD) for continuous outcomes and pool the results using a random-effects
model. However, we did not pool the results from trials that were too diverse in participant characteristics and interventions. This
is because a meta-analysis is particularly interested in the effect of a specific intervention (compared with an adequate control) on a
specific outcome in a specific population.
Furthermore, for trials not in the meta-analysis, we calculated mean difference (MD) rather than SMD for continuous outcomes as
the individual effect size. This is because SMD was used to facilitate the pooling of results from trials using different scales for a same
outcome, but for individual trials MD is preferable as it is more interpretable than SMD.
Subgroup analyses
In the 2008 review, we had planned to perform a subgroup analysis for ’duration of treatment’. In the current review, we changed this
to the ’amount of intervention’. The latter is a better expression to quantify an intervention, as it involves both dose/intensity and
duration of the intervention.
In the 2008 review, we planned to perform a subgroup analysis for ’length of follow-up’. In the current review, we did not perform this
subgroup analysis but performed separate analyses for outcomes assessed at different time points after treatment.
In the current review, we added an analysis for time window from stroke onset to recruitment. This is based on our hypothesis
that different factors may contribute to PSF along its natural history, thus the efficacy of the same intervention may be different for
participants at different time points after stroke.
We had intended to perform subgroup analyses for different types of interventions, but each identified intervention was tested in a
single trial, thus we could only broadly categorise them as pharmacological interventions and non-pharmacological interventions. We
also summarised the individual results for each intervention in a separate section.
We had intended to perform subgroup analyses for sources of participants, amount of intervention and time of recruitment since stroke,
but this was not achieved because these subgroups were pre-specified to be performed under a same type intervention, but the included
trials each used a different intervention.
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Sensitivity analyses
In the 2008 review, we planned to perform a sensitivity analysis for publication types. We did not perform this analysis in the current
review, because we do not think publication status related to any risk of bias.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents [therapeutic use]; Drugs, Chinese Herbal [therapeutic use]; Fatigue [etiology; ∗therapy];Mindfulness [methods];
Randomized Controlled Trials as Topic; Stress, Psychological [prevention & control]; Stroke [∗complications; psychology]
MeSH check words
Female; Humans; Male
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